var title_f8_45_8912="MRI of Thornwaldt cyst";
var content_f8_45_8912=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F62256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F62256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI of Thornwaldt cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_45_8912=[""].join("\n");
var outline_f8_45_8912=null;
var title_f8_45_8913="Resection of right colon mesentery";
var content_f8_45_8913=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Resection of right colon mesentery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 345px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the incision of the perintoneal surface of the mesentery and ligattion of the mesenteric vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_45_8913=[""].join("\n");
var outline_f8_45_8913=null;
var title_f8_45_8914="Patient information: Post-traumatic stress disorder (The Basics)";
var content_f8_45_8914=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/57/12179\">",
"         Patient information: Depression (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/58/22434\">",
"         Patient information: Insomnia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/6/24675\">",
"         Patient information: Medicines for depression (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/6/13413\">",
"         Patient information: Depression in adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/41/20116\">",
"         Patient information: Depression in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/21/29013\">",
"         Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/24/21894\">",
"         Patient information: Depression treatment options for adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Post-traumatic stress disorder (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/post-traumatic-stress-disorder-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H30116649\">",
"      <span class=\"h1\">",
"       What is post-traumatic stress disorder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Post-traumatic stress disorder, or &ldquo;PTSD,&rdquo; is a condition that can happen after people see or live through a trauma. A trauma is an intense event that involves serious injury or death, or the chance of serious injury or death. This can include medical events, such as a heart attack or surgery. PTSD can cause nightmares, upsetting memories, anxiety, and other symptoms.",
"     </p>",
"     <p>",
"      Not everyone who sees or lives through a trauma will get PTSD. Doctors do not know why some people get PTSD and others don&rsquo;t.",
"     </p>",
"     <p>",
"      PTSD can happen at any age.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30116664\">",
"      <span class=\"h1\">",
"       What are the symptoms of PTSD?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of PTSD include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Reliving the trauma through thoughts and feelings &ndash; People can have upsetting memories, nightmares, or flashbacks. Flashbacks are when people &ldquo;see&rdquo; or feel the trauma over and over again.",
"       </li>",
"       <li>",
"        Feeling &ldquo;numb&rdquo; and avoiding certain people or places &ndash; People avoid thinking about the trauma and avoid people and places that remind them of it. Some people also feel &ldquo;numb.&rdquo; They might not enjoy activities they used to enjoy or feel part of the world around them.",
"       </li>",
"       <li>",
"        Having intense feelings, such as anger, fear, or worry &ndash; People might frighten or startle easily. Many people have trouble sleeping.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The symptoms of PTSD usually start within 3 months of a trauma, but sometimes they start years later. The symptoms often affect a person&rsquo;s job, relationships, or daily life.",
"     </p>",
"     <p>",
"      Symptoms of PTSD can come and go. They might return when people are under stress or see or hear something that reminds them of the trauma.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30116687\">",
"      <span class=\"h1\">",
"       How can my doctor or nurse tell if I have PTSD?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse should be able to tell if you have it by learning about your symptoms, asking you questions, and doing an exam.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30116702\">",
"      <span class=\"h1\">",
"       How is PTSD treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;PTSD is treated with 1 or both of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines &ndash; Doctors can use different types of medicines to treat PTSD. The right one for you will depend on your symptoms and the medicine&rsquo;s side effects. People usually start feeling better after they have been on medicine for a few weeks.",
"       </li>",
"       <li>",
"        A type of talk therapy called cognitive-behavioral therapy, or &ldquo;CBT&rdquo; &ndash; CBT involves meeting with a therapist to talk about your feelings and thoughts. Your therapist will do certain activities with you that can reduce your symptoms. Different types of therapists can do CBT, including psychologists, psychiatrists, and social workers. You can work one-on-one with a therapist to have CBT. You can also have CBT as part of group therapy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30116717\">",
"      <span class=\"h1\">",
"       When should I get help?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are having trouble coping because of your PTSD symptoms, you should do 1 or both of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        See a doctor to start treatment with medicine",
"       </li>",
"       <li>",
"        See a therapist who is trained in CBT to start therapy",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you are thinking of hurting yourself, or if you feel that life isn&rsquo;t worth living, you should get help right away:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        If you see a therapist or doctor for your PTSD, call him or her right away.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        If you do not see a therapist or doctor, or if you can&rsquo;t reach him or her right away, call 9-1-1 or go to the emergency room.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30116732\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=see_link\">",
"       Patient information: Depression (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/6/24675?source=see_link\">",
"       Patient information: Medicines for depression (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/58/22434?source=see_link\">",
"       Patient information: Insomnia (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"       Patient information: Depression in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"       Patient information: Depression treatment options for adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=see_link\">",
"       Patient information: Depression in adolescents (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/21/29013?source=see_link\">",
"       Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?8/45/8914?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16594 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-04D01F2D42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_45_8914=[""].join("\n");
var outline_f8_45_8914=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30116649\">",
"      What is post-traumatic stress disorder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30116664\">",
"      What are the symptoms of PTSD?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30116687\">",
"      How can my doctor or nurse tell if I have PTSD?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30116702\">",
"      How is PTSD treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30116717\">",
"      When should I get help?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30116732\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=related_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=related_link\">",
"      Patient information: Depression in adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/21/29013?source=related_link\">",
"      Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=related_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/58/22434?source=related_link\">",
"      Patient information: Insomnia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/6/24675?source=related_link\">",
"      Patient information: Medicines for depression (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_45_8915="Effects of procainamide on conduction";
var content_f8_45_8915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    Effects of procainamide on an abnormal His-Purkinje conduction system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 307px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These tracings were taken from a 58 year-old male with syncope. The baseline 12-lead electrocardiogram demonstrated sinus rhythm with prolonged AV conduction and a left bundle branch block with left axis deviation. Surface leads represented are I, II, III, and V1. Intracardiac tracings shown are the high right atrium (HRA), the distal His bundle electrogram (HIS d), the proximal His bundle electrogram (HIS 2), and the right ventricular apex (RVa). The left side of Panel A shows a baseline H-V interval of 68 msec. The right side of Panel A demonstrates prolongation of the H-V interval to 100 msec after the administration of procainamide indicating severe His-Purkinje conduction disease. Panel B (same lead schema) demonstrates high right atrial pacing at 400 msec (150 beats per minute) with infra-Hisian block (arrow) after the administration of procainamide confirming severe His-Purkinje disease.",
"    <div class=\"footnotes\">",
"     A: atrial depolarization; AV: atrioventricular; H: His bundle depolarization; ms: milliseconds; V: ventricular depolarization.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph J Germano, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_45_8915=[""].join("\n");
var outline_f8_45_8915=null;
var title_f8_45_8916="Mechanism for anemia of chronic disease";
var content_f8_45_8916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Mechanism for the anemia of chronic disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 510px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A proposed mechanism for the anemia of chronic disease (ACD) is shown here. In the presence of infection, inflammation, or malignancy, the macrophage is stimulated to produce interleukin-6 (IL-6) and interleukin-1 beta (IL-1&beta;), which induce the production of hepcidin by the liver. Hepcidin, in turn, through its interaction with the iron export protein ferroportin, inhibits iron absorption from the gastrointestinal tract and decreases release of iron from macrophages. Both effects lead to the reduced plasma iron levels (hypoferremia) characteristic of ACD. Inflammatory cytokines such as IL-1&beta; and TNF-&alpha;&nbsp; reduce erythropoietin production and the efficiency of erythropoiesis, which are also components of ACD.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_45_8916=[""].join("\n");
var outline_f8_45_8916=null;
var title_f8_45_8917="Choline magnesium trisalicylate: Pediatric drug information";
var content_f8_45_8917=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Choline magnesium trisalicylate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?41/43/42677?source=see_link\">",
"    see \"Choline magnesium trisalicylate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/35/42548?source=see_link\">",
"    see \"Choline magnesium trisalicylate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Non-narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipyretic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Salicylate",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/43/42677?source=see_link\">",
"      see \"Choline magnesium trisalicylate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (based on",
"     <b>",
"      total salicylate content",
"     </b>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 30-60 mg/kg/day given in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 500 mg to 1.5 g 1-3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F150916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral: 500 mg/5 mL (240 mL) [choline salicylate 293 mg and magnesium salicylate 362 mg per 5 mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F150900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food or milk to decrease GI upset; may be mixed with fruit juice just before drinking; do not administer with antacids",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of osteoarthritis, rheumatoid arthritis, and other arthritides; treatment of acute painful shoulder, mild to moderate pain, and fever",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F150963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, headache, lethargy, lightheadedness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, dyspepsia, epigastric, heartburn, nausea, pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing impairment, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anorexia, asthma, bruising, confusion, duodenal ulceration, dysgeusia, edema, epistaxis, erythema multiforme, esophagitis, hallucinations, hearing loss (irreversible), increased BUN, increased creatinine, increased hepatic enzymes, gastric ulceration, occult bleeding, pruritus, rash, weight gain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to salicylates, any component, or other nonacetylated salicylates; history of asthma, urticaria, or allergic-type reaction to aspirin, or other NSAIDs; patients with the \"aspirin triad\" [asthma, rhinitis (with or without nasal polyps), and aspirin intolerance] (fatal asthmatic and anaphylactoid reactions may occur in these patients)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with extreme caution in patients with impaired renal function, erosive gastritis or peptic ulcer",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use salicylates in children and teenagers who have or who are recovering from chickenpox or flu symptoms (due to the association with Reye's syndrome); when using salicylates, changes in behavior (along with nausea and vomiting) may be an early sign of Reye's syndrome; instruct patients and caregivers to contact their healthcare provider if these symptoms occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F150909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Salicylates may diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Salicylates may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the anticoagulant effect of Salicylates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Salicylates may increase the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Salicylates may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Weigh potential benefits of drotrecogin against increased bleeding risk in patients who have received  platelet inhibitors including aspirin (over 650 mg daily within 1 week). Monitor for bleeding and stop infusion if clinically important bleeding occurs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ginkgo Biloba: May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Salicylates may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Salicylates may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Acid Phosphate: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: Salicylates may diminish the therapeutic effect of Probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of other Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Salicylates may increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varicella Virus-Containing Vaccines: Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F150912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C/D (3rd trimester) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F150925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Due to the known effects of other salicylates (closure of ductus arteriosus), use during late pregnancy should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum salicylate levels; serum magnesium with high doses or in patients with decreased renal function",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1051731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Salicylate blood levels for anti-inflammatory effect: 150-300 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Analgesia and antipyretic effect: 30-50 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits prostaglandin synthesis; acts on the hypothalamus heat-regulating center to reduce fever; blocks the generation of pain impulses",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: From stomach and small intestine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Readily distributes into most body fluids and tissues; crosses the placenta; appears in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90% to 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic microsomal enzyme system",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Dose-dependent, ranging from 2-3 hours at low doses to 30 hours at high doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 20-35 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 10% excreted as unchanged drug",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/35/42548?source=see_link\">",
"      see \"Choline magnesium trisalicylate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; notify physician if ringing in ears, persistent GI pain, GI bleeding, or changes in behavior (along with nausea and vomiting) occur",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Salicylate salts do not inhibit platelet aggregation and, therefore, should not be substituted for aspirin in the prophylaxis of thrombosis (ie, for aspirin's antiplatelet effects)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berde C, Ablin A, Glazer J, et al, &ldquo;American Academy of Pediatrics Report of the Subcommittee on Disease-Related Pain in Childhood Cancer,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(5 Pt 2):818-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8917/abstract-text/2216644 /pubmed\" id=\"2216644 \" target=\"_blank\">",
"        2216644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13153 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-1AFF26D322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_45_8917=[""].join("\n");
var outline_f8_45_8917=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051728\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051721\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150916\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150900\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051733\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051732\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150963\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051736\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051720\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051719\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299035\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150909\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150912\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150925\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051727\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051731\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051718\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051735\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051726\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051737\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13153\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13153|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/43/42677?source=related_link\">",
"      Choline magnesium trisalicylate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/35/42548?source=related_link\">",
"      Choline magnesium trisalicylate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_45_8918="Teriflunomide: Drug information";
var content_f8_45_8918=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Teriflunomide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/40/30341?source=see_link\">",
"    see \"Teriflunomide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F15035591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15098019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aubagio&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F15125279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Pyrimidine Synthesis Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15125380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Multiple sclerosis (MS):",
"     </b>",
"     Adults: Oral: 7 mg or 14 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15125382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment is needed in patients with mild-to-severe renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15125383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment: No dosage adjustment needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment: Use contraindicated (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F15125381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     ALT elevations &gt;3 times ULN: Discontinue teriflunomide and initiate cholestyramine or activated charcoal to enhance elimination",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <i>",
"      Drug elimination procedure:",
"     </i>",
"     To achieve nondetectable serum concentrations (&lt;0.02 mg/L) of teriflunomide administer either of the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cholestyramine: 8 g every 8 hours for 11 days. If not tolerated, may decrease to 4 g every 8 hours for 11 days. The 11 days do not need to be consecutive unless plasma concentrations need to be lowered rapidly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Activated charcoal: 50 g every 12 hours for 11 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Both treatments have successfully lead to &gt;98% decrease in teriflunomide concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F15098020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aubagio&reg;: 7 mg, 14 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F15125278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15125277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM322204.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM322204.pdf",
"     </a>",
"     must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15125399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15035593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of relapsing forms of multiple sclerosis (MS)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15125131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (19% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Alopecia (10% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypophosphatemia (5% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (15% to 18%), nausea (9% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenia (2% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (12% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (4%), palpitation (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Anxiety (3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (3% to 4%), acne (3%), burning sensation (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hyperkalemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain (5% to 6%), toothache (4%), viral gastroenteritis (2% to 4%), weight loss (2% to 3%), abdominal distension (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Cystitis (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Thrombocytopenia (10%), lymphocytopenia (7% to 10%), leukopenia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: GGT increased (3% to 5%), AST increased (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (9% to 10%), musculoskeletal pain (4% to 5%), myalgia (3% to 4%), sciatica (3%), carpal tunnel syndrome (1% to 3%), peripheral neuropathy (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision (3%), conjunctivitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Renal failure (transient, 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (9%), bronchitis (8%), sinusitis (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Herpes simplex (4%), seasonal allergy (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Cytomegalovirus hepatitis reactivation, jaundice, infection, MI",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15125286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hepatic impairment; concomitant use with leflunomide; women of childbearing age who will not use contraception reliably; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15125287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Rare cases of dermatologic reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis) have been reported with leflunomide, therefore patients taking teriflunomide may also be at risk; discontinue if evidence of severe dermatologic reaction occurs, and begin drug elimination procedures (eg, cholestyramine, activated charcoal).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Use of leflunomide has been associated with rare reports of hepatotoxicity, hepatic failure, and death, therefore, a similar risk is expected with teriflunomide. Treatment should not be initiated in patients with pre-existing acute or chronic liver disease or ALT &gt;2 x ULN; use is contraindicated in patients with severe impairment. Use caution in patients with concurrent exposure to potentially hepatotoxic drugs. Monitor ALT levels at least monthly for first 6 months during therapy; discontinue if ALT &gt;3 x ULN occurs and, if hepatotoxicity is likely teriflunomide-induced, start drug elimination procedures",
"     </b>",
"     (eg, cholestyramine, activated charcoal) and monitor liver function tests weekly until normalized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Severe hyperkalemia (&gt;7.0 mmol/L) has been reported. Monitor levels in patients with symptoms or acute renal failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Increases in blood pressure have been reported; monitor at initiation of therapy and periodically thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections: May increase susceptibility to infection, including opportunistic pathogens. Severe infections, sepsis, and fatalities have been reported with leflunomide. One case of fatal sepsis has been reported with teriflunomide. Not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections. Caution should be exercised when considering the use in patients with a history of new/recurrent infections, with conditions that predispose them to infections, or with chronic, latent, or localized infections. Patients who develop a new infection while undergoing treatment should be monitored closely; consider discontinuation of therapy and drug elimination procedures (eg, cholestyramine, activated charcoal) if infection is serious.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Interstitial lung disease: Use of leflunomide has been associated (rarely) with interstitial lung disease, therefore patients taking teriflunomide may also be at risk; discontinue in patients who develop new onset or worsening of pulmonary symptoms. Drug elimination procedures (eg, cholestyramine, activated charcoal) should be considered if evidence of interstitial lung disease; fatal outcomes have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignancy: Use may affect defenses against malignancies; impact on the development and course of malignancies is not fully defined. As compared to the general population, an increased risk of lymphoma has been noted in clinical trials with use of some immunosuppressive medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: Cases of peripheral neuropathy have been reported; use with caution in patients &gt;60 years of age, receiving concomitant neurotoxic medications or patients with diabetes; discontinue if evidence of peripheral neuropathy occurs and begin drug elimination procedures (eg, cholestyramine, activated charcoal).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal effects: Transient acute renal failure, most likely due to acute uric acid nephropathy, has been reported. Increased serum creatinine typically occurred 12 weeks to 2 years after the first dose; serum creatinine usually normalized with continued use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic disorders: Use with caution in patients with a prior history of significant hematologic abnormalities; avoid use with bone marrow dysplasia. Neutropenia, leukopenia, and thrombocytopenia have been reported in clinical trials. Use of leflunomide has been associated with rare pancytopenia, agranulocytosis, and thrombocytopenia, therefore, a similar risk may be expected with teriflunomide. Monitoring of hematologic function is required; discontinue if evidence of bone marrow suppression and begin drug elimination procedures (eg, cholestyramine, activated charcoal).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tuberculosis: Safety has not been established in patients with latent tuberculosis infection. Patients should be screened for tuberculosis and if necessary, treated prior to initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppressants: If coadministered with other potential immunosuppressive agents or switching from teriflunomide to another known immunosuppressant, increased monitoring for hematological adverse effects is necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy/women of childbearing potential:",
"     <b>",
"      [U.S. Boxed Warning]: Based on animal data, teriflunomide may cause major birth defects if used in pregnant women. Teriflunomide is contraindicated in pregnant women or women of childbearing potential who are not using reliable contraception. Pregnancy must be avoided during therapy or prior to completing the accelerated elimination treatment protocol.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug elimination procedure: Due to variations in clearance, it may take up to 2 years to reach low levels of teriflunomide metabolite serum concentrations. A drug elimination procedure using cholestyramine or activated charcoal is recommended when a more rapid elimination is needed. If a response to teriflunomide had already been observed, the use of a rapid elimination procedure may result in the return of disease activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there is no data available concerning secondary transmission of live vaccines in patients receiving therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15255949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of BCRP;",
"     <b>",
"      Inhibits",
"     </b>",
"     BCRP, CYP2C8 (moderate), SLCO1B1;",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15255947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Teriflunomide. Management: Unless using this combination to intentionally enhance teriflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is unlikely to be effective at avoiding the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caffeine: Teriflunomide may decrease the serum concentration of Caffeine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Charcoal, Activated: May decrease the serum concentration of Teriflunomide. Management: Unless using this combination to intentionally enhance teriflunomide elimination, consider an alternative to charcoal when possible. Separating drug administration is not likely to be effective at avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: May enhance the adverse/toxic effect of Teriflunomide. Leflunomide may increase the serum concentration of Teriflunomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Teriflunomide may increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Teriflunomide may decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15125282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15125283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies conducted using doses lower than the expected human exposure.",
"     <b>",
"      [U.S. Boxed Warning]: Based on animal data, teriflunomide may cause major birth defects if used in pregnant women. Teriflunomide is contraindicated in pregnant women or women of childbearing potential who are not using reliable contraception. Pregnancy must be avoided during therapy or prior to completing the accelerated elimination treatment protocol.",
"     </b>",
"     Pregnancy must be excluded prior to initiating treatment. Women of childbearing potential should not receive therapy until pregnancy has been excluded, they have been counseled concerning fetal risk, and reliable contraceptive measures have been confirmed. Following treatment, pregnancy should be avoided until undetectable serum concentrations (&lt;0.02 mg/L) are verified. This may be accomplished by the use of an enhanced drug elimination procedure using cholestyramine or activated charcoal powder. If pregnancy occurs during treatment, discontinue therapy and initiate the accelerated elimination procedure. Pregnant women exposed to teriflunomide should be registered with the pregnancy registry (800-745-4447, option 2). Teriflunomide is also found in semen. Males and their female partners should use reliable contraception during therapy. Males taking teriflunomide who wish to father a child should consider discontinuing therapy and using the accelerated elimination procedure to decrease the potential risk of fetal exposure. (",
"     <b>",
"      Note:",
"     </b>",
"     Without use of the accelerated elimination procedure, teriflunomide may remain in the serum for up to 2 years)",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15125284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15125285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known whether teriflunomide is secreted in human milk. Because the potential for serious adverse reactions exists in the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F15125398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Aubagio Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7 mg (28): $4153.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14 mg (28): $4153.85",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15125401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC within 6 months of initiation and periodically thereafter based on signs/symptoms of infection; serum potassium, serum creatinine, serum transaminase and bilirubin within 6 months of initiation of therapy and monthly during the initial 6 months of treatment. In addition, monitor for signs/symptoms of severe infection, abnormalities in hepatic function tests, symptoms of hepatotoxicity, and blood pressure (baseline and periodically thereafter). Screen for tuberculosis and pregnancy prior to therapy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15125351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teriflunomide is an immunomodulatory agent that inhibits pyrimidine synthesis, resulting in antiproliferative and anti-inflammatory effects. It may reduce the number of activated lymphocytes in the CNS.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15125353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : I.V.: 11 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Primarily by hydrolysis to minor metabolites; secondary pathways include oxidation, conjugation, and N-acetylation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Median: 18-19 days; enterohepatic recycling appears to contribute to the long half-life of this agent, since activated charcoal and cholestyramine substantially reduce plasma half-life",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (~38%); urine (~23%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86616 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_45_8918=[""].join("\n");
var outline_f8_45_8918=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15035591\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15098019\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125279\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125380\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125382\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125383\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125381\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15098020\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125278\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125277\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125399\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15035593\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125131\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125286\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125287\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15255949\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15255947\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125282\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125283\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125284\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125285\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125398\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570454\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125401\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125351\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125353\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86616\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86616|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/40/30341?source=related_link\">",
"      Teriflunomide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_45_8919="Management of acquired maxillary defects: Prosthetic rehabilitation";
var content_f8_45_8919=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of acquired maxillary defects: Prosthetic rehabilitation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/45/8919/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/45/8919/contributors\">",
"     Jean-Francois Bedard, DMD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/45/8919/contributors\">",
"     Joseph A Toljanic, DDS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/45/8919/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/45/8919/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/45/8919/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/45/8919/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/45/8919/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prosthetic rehabilitation provides the option of regaining functional integrity and cosmesis while improving the patient's quality of life during or after surgical management of head and neck cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The prosthesis used to close an opening of the hard palate is termed an obturator. The main objectives of prosthetic rehabilitation are to provide an obturator prosthesis that restores orofacial functions, such as deglutition, control of secretions, mastication and phonetics, and also to aesthetically replace the missing orofacial structures [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current prosthodontic options for the management of the acquired hard palate defect will be reviewed here. The prosthodontic management of soft palate defects, mandibular and facial defects are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39815?source=see_link\">",
"     \"Mandibular and palatal reconstruction in patients with head and neck cancer\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT PLANNING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial planning for patients about to undergo treatment of head and neck cancer should include evaluation by a prosthodontist. Even if surgical reconstruction is planned, dental prosthesis may be considered as part of the definitive rehabilitation. The expertise of a dental specialist is necessary to address subtle dentoalveolar concerns that may impact decision making, such as plane of occlusion, articulation of teeth, tooth mobility, preexisting temporomandibular joint dysfunctions, orodental parafunctional habits (eg, nocturnal grinding or clenching of the teeth), preexisting benign conditions, anatomic variations and postoperative orodental care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=see_link\">",
"     \"Oral toxicity associated with chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31545?source=see_link\">",
"     \"Speech and swallowing rehabilitation of the patient with head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A complete orofacial examination should be performed. The surgical plan and the postsurgical complications that will have to be addressed prosthodontically should be explained to the patient. At this time, a detailed evaluation of the existing dentoalveolar condition should be undertaken. Restorative and periodontal treatments, as well as extractions should be planned. Depending on the preliminary design of the resection, even compromised teeth should be potentially considered as supports for a prosthesis.",
"   </p>",
"   <p>",
"    Splinting teeth with a conventional bridge or a supracrestal bar (Hader or Dolder type) might prove beneficial for retention, support and stability of a removable obturator. However, torquing forces should be evaluated and the design modified accordingly. Preexisting conditions that may impact on successful prosthodontic outcome (eg, the presence of a maxillary torus or bucco-alveolar exostosis that will not be included within the resection) should also be evaluated and corrected prior to definitive surgery. A preexisting fixed partial denture that crosses the planned resection cut is easily sectioned prior to the planned surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnostic casts of the dental arches should be obtained prior to surgery. They are important for consultation between the surgeon and prosthodontist, as well as for the fabrication of a surgical obturator prosthesis. Other considerations can also be discussed presurgically, and may include endosseous dental or craniofacial implants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SURGICAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary objective of surgery is the complete eradication of the tumor, which requires adequate surgical margins to reduce the risk of local recurrence. Adjacent structures should be resected if necessary to obtain negative margins. However, a few surgical precautions taken can result in a postoperative defect that can be effectively obturated prosthetically [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Palatal mucosal incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;A simple consideration that has a positive impact on prosthesis function is to provide for a band of keratinized palatal mucosa to cover the medial aspect of the exposed residual bony palate. This can be accomplished by making the primary palatal mucosal incision at least 5 mm lateral to the osseous cut. This loose band of dense keratinized tissue can then be sutured to the septum or nasal floor, covering the medially exposed bony palate. This area forms the fulcrum for rotation of the obturator prosthesis, and keratinized tissue will more favorably accept friction from the prosthesis than nonkeratinized nasal mucosa. A split-thickness skin graft should be considered if keratinized palatal mucosa is not available [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Preservation of teeth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strategically positioned teeth, such as canines [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/4\">",
"     4",
"    </a>",
"    ] and terminal molars, should be preserved if adjacent negative margins can be achieved. It should be emphasized that even weaker teeth can be considered as potential abutments for an obturator prosthesis. Even if some of those teeth will eventually be extracted, they will have provided a service, permitting adaptation to the removable prosthesis, and a transition from a tooth-supported prosthesis to a soft tissue-supported prosthesis.",
"   </p>",
"   <p>",
"    Equally important is the preservation of adequate osseous support to the tooth adjacent to the transverse alveolar cut; the line of resection should pass through the socket of the adjacently extracted tooth [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/4\">",
"     4",
"    </a>",
"    ]. If the surgeon cuts between two existing teeth, destroying the septum of bone between them, the tooth left as the most distal tooth will likely be lost rapidly, not having any bone on its distal surface to retain it.",
"   </p>",
"   <p>",
"    Teeth that are located within a planned or prior radiation treatment field should be maintained meticulously. This is because compromised osseous vasculature can potentially complicate future extraction procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link&amp;anchor=H722455156#H722455156\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Dental issues'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link&amp;anchor=H3822453#H3822453\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Osteoradionecrosis and soft tissue necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Preservation of disease-free osseous structures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts should be made to conserve the premaxilla (anterior maxilla) if the lesion or defect is situated posteriorly. Conversely, if an anterior defect will be created, saving as much of the posterior hard palate as possible will maximize prosthetic support, stability and retention, and provide a sound osseous structure for the placement of endosseous implants [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Split-thickness skin graft",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a cheek or lip flap is sutured after surgery and left to granulate, the resulting internal mucosa provides a poorly tolerant surface for frictional abrasion from the prosthesis, especially if radiation therapy is included in the treatment plan. For this reason, a split-thickness graft should be considered to line the inner surface of the reflected lip, and possibly the entire surface of intraoral defect. Nonkeratinized respiratory epithelium is not ideal to resist trauma from significant friction from the obturator prosthesis surface. The prosthesis will be more easily tolerated if the periphery of the defect is lined with a graft that provides keratinized mucosa rather than fragile mucous membranes. The keratinized skin graft surface will provide a more tolerant surface to frictional forces, which is especially valuable if radiation therapy will be used, as well as create a \"scar-band\" that the prosthesis can engage and \"rest\" on. The graft should also limit contracture of the cheek, and increase tissue flexibility [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Soft palate considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The entire soft palate typically should be resected if less than one-third of its posterior aspect will remain postresection. This remnant may lack innervation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    normal function, and can compromise prosthetic function during speech and deglutition [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/7\">",
"     7",
"    </a>",
"    ]. However for a patient with an edentulous maxilla, an intact posterior band of soft palate, even if neuromuscularly compromised, will provide additional retention and support for an obturator [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Elimination of nasal turbinates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nasal turbinates should be considered for removal. This is because these anatomic structures often prevent maximum extension over the remaining palatal shelf and nasal cavity to obtain an optimal seal [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Posterolateral support",
"    </span>",
"    &nbsp;&mdash;&nbsp;A stable well-supported prosthesis needs three separate contact points for anchoring. Special surgical attention should be given to the posterolateral aspect of the defect to provide an osseous area for prosthesis support. The prosthesis function will be enhanced if the zygomatico-temporal bone can be used in this manner.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vestibular depth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention should be directed to the remaining alveolar ridge at the time of closure. Careful suturing of the flaps to create a labioalveolar vestibule of adequate depth, and minimizing second intention healing of these tissues will also permit optimal prosthetic outcome. The surgical obturator prosthesis may contain a flange that extends into the vestibule, preventing undesirable fibrous attachment to the crest of the alveolar ridge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Implants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of procedures may aid considerably in restoring oro-dento-facial function, and be performed immediately after resection, or following a variable waiting period or healing time depending on the size of the defect, the presentation of the residual supporting structures and the desires of the patient. They include but are not limited to: endosseous dental or craniofacial implants [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/4,8-13\">",
"     4,8-13",
"    </a>",
"    ], transzygomatic Steinmann implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/14\">",
"     14",
"    </a>",
"    ], titanium hollow screw reconstruction plate (THORP) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/15\">",
"     15",
"    </a>",
"    ], and AO-reconstruction plate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Removal of coronoid process of mandible",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mandibular coronoid process may interfere with maximal posterolateral extension of the prosthesis, especially in patients with coexisting contralateral mandibular defects. In some cases, if additional means of obturator prosthesis retention are not available, removal of the coronoid process may prove beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PROSTHODONTIC REHABILITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;General prosthodontic principles apply to most maxillofacial prosthetics situations. Adequate retention, support and stability are necessary to ensure the success of rehabilitation. Because of the unconventional presentation of the defect, those principles must be fully understood as they will have to be optimized, contoured, and sometimes violated, with ingenuity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Teeth may be preserved contralateral to the resection, or anterior or posterior to it, depending on the clinical situation. As previously noted, even teeth with a poor or uncertain prognosis may provide good service, if only for a few years, helping the patient to adapt to the prosthesis. Presurgical treatment planning is the key in critical decision making as to which teeth need to be sacrificed and which should be preserved. When properly restored and incorporated into the design of the prosthesis, salvaged teeth dramatically improve the ability of a patient to tolerate a removable obturator prosthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/6,19-21\">",
"     6,19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Immediate (surgical) obturator prostheses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prosthodontic rehabilitation of an acquired hard palate defect should be initiated at the time of surgery, in an effort to maximize the quality of life of the patient. This is done by the insertion and fixation of an immediate (surgical) obturator prosthesis. There are a number of advantages associated with such a procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Provides support for surgical packing which will extend into the created defect",
"     </li>",
"     <li>",
"      Prevents unfavorable fibrous attachment",
"     </li>",
"     <li>",
"      Reduces extent of oral contamination of the defect",
"     </li>",
"     <li>",
"      Minimizes phonetic impairment",
"     </li>",
"     <li>",
"      Facilitates deglutition and post-surgical control of secretions",
"     </li>",
"     <li>",
"      Minimizes psychological impact of surgery",
"     </li>",
"     <li>",
"      Maintains oro-dental aesthetics",
"     </li>",
"     <li>",
"      Provides diagnostic information for later permanent treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The surgical obturator prosthesis is fabricated on a cast obtained from an impression made at the time of the pretreatment dental examination and based upon the preliminary design drawn by the surgeon at the time of consultation. Numerous techniques have been described but usually it is fabricated using autopolymerizing acrylic resin (methyl methacrylate) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/4,22\">",
"     4,22",
"    </a>",
"    ]. The immediate obturator prosthesis will have the configuration of a base plate appropriately extending in the labio-buccal vestibule, and maintaining palatal continuity. It covers as much tissues as possible, including both alveolar ridges, and the entire palatal surface, including the planned portion to be resected. The patient's existing denture can also be utilized, if available, with or without modifications.",
"   </p>",
"   <p>",
"    The immediate obturator prosthesis is adjusted if necessary, and ligated into position following tumor resection but before flap closure. Perforations are strategically positioned in the surgical obturator to accommodate the passing of stainless steel wires or screws. The obturator may be attached and stabilized using circumdental ligation, circumzygomatic suspension wire ligation, transzygomatic wire ligation, transalveolar wire ligation, palatal screw fixation, or a combination of the above. Alternatively, the surgical obturator prosthesis can be designed as a removable prosthesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Transitional obturator prosthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is brought to the dental clinic for removal of the surgical obturator prosthesis and insertion of a transitional obturator prosthesis after a minimum of 7 to 10 days and when",
"    <span class=\"nowrap\">",
"     s/he",
"    </span>",
"    is in a stable condition. The wires are cut and retrieved, the prosthesis and packing removed, and the defect examined.",
"   </p>",
"   <p>",
"    The transitional obturator prosthesis may be fabricated on the original cast recovered from the primary impression made at the time of dental evaluation and a new acrylic resin base plate. Alternatively, the immediate obturator prosthesis or existing denture prosthesis can also be modified for use depending on the situation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/23\">",
"     23",
"    </a>",
"    ]. The transitional obturator prosthesis is then extended into the defect using tissue conditioning material. Small additions are made consecutively until an appropriately retentive, stable and supported prosthesis is obtained.",
"   </p>",
"   <p>",
"    The patient is instructed regarding the care of the prosthesis and is seen regularly for evaluation and adjustment of the resilient lining to accommodate tissue changes during the healing phase [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/24\">",
"     24",
"    </a>",
"    ]. Artificial teeth can be added to this transitional prosthesis, if desired, and restorative dentistry, periodontal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endodontic treatments can be performed during this interim healing phase to optimize remaining structures for the definitive prosthesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Definitive (permanent) obturator prosthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Planning for definitive obturation can begin once adequate healing has occurred, and radiation therapy is completed (usually after three to four months). New impressions of the defect will be made for the first time here. Impressions can be made using the diagnostic information obtained from the transitional obturator prosthesis in terms of function (speech, deglutition and control of secretions, retention, support, stability, occlusion) and aesthetics.",
"   </p>",
"   <p>",
"    General prosthodontic guidelines are followed and adapted to the individual situation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/25\">",
"     25",
"    </a>",
"    ]. If the maxillary arch is partially dentate, a cast-metal removable partial denture (RPD) should be considered to take advantage of the presence of teeth. A swing-lock RPD may be a practical treatment option, as well as the use of channel rests. Stress-breaking capacities should also be incorporated into the RPD design and have historically included the use of disengaging infra-bulge clasp systems, fissured major connector and cross-tooth reciprocation. If completely edentulous, maximum extension within tissue tolerance should be obtained.",
"   </p>",
"   <p>",
"    Several factors should be considered when using a removable prosthesis to obturate an oral defect [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The obturator prosthesis will undergo severe functional movements during mastication, speaking and swallowing. The larger the resection, the more significant the movement as there is less available structures to assist in the retention of the prosthesis.",
"     </li>",
"     <li>",
"      Soft tissue changes will be especially important during the first year after surgery and radiation therapy.",
"     </li>",
"     <li>",
"      Prosthetic palatopharyngeal competency will have to be compromised; a nasopharyngeal space will have to exist to allow nasal breathing and pharyngeal wall movements, yet have to be closed for deglutition and proper phonetics.",
"     </li>",
"     <li>",
"      Extension of the obturator prosthesis into the defect depends upon the need for additional retention support and stability, as well as on the quality of bearing mucosa.",
"     </li>",
"     <li>",
"      The weight of the prosthesis should be kept to a minimum by using a cup shape or hollow bulb design for the obturator portion of the prosthesis.",
"     </li>",
"     <li>",
"      The superior portion of the obturator prosthesis should be designed to encourage postero-medial drainage of secretions.",
"     </li>",
"     <li>",
"      Bilateral simultaneous occlusal contacts with reduced lateral interferences should be obtained.",
"     </li>",
"     <li>",
"      Chewing should be discouraged on the side of the defect. Support on the side of the defect is compromised by the hole in the maxilla extending into the nasal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sinusal and or orbital cavities. Forces from chewing will likely cause discomfort, and further destabilize the obturator prosthesis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When possible, maximum extension on supporting structures is beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/4\">",
"     4",
"    </a>",
"    ]. This is obtained by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Engaging the lateral scar band",
"     </li>",
"     <li>",
"      Providing proper tissue contact superolaterally",
"     </li>",
"     <li>",
"      Nasal extension (anteriorly and medially if septum is absent)",
"     </li>",
"     <li>",
"      Posterior extension to obtain support from superior aspect of soft palate (when a band remains)",
"     </li>",
"     <li>",
"      Avoidance of any contact on the midsuperior aspect of medial wall or the nasal turbinates",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The post-insertion period may be more eventful than with most conventional prosthodontic situations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Additional surgical resections, concomitant chemotherapy and radiation therapy, as well as individual variations make each presentation unique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dealing with the replacement of missing teeth alone can be challenging. With the additional loss of part or most of the supporting tissues, the likelihood of fabricating a prosthesis that will meet the needs and expectations of the patient dramatically decreases. Patients should be educated with regard to realistic expectations whether a partial maxillectomy, complete maxillectomy, or bilateral maxillectomies are to be performed.",
"   </p>",
"   <p>",
"    In one study, questionnaires were sent to 104 patients who had received a maxillary prosthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/2\">",
"     2",
"    </a>",
"    ]. The analysis revealed that early prosthesis fabrication served to enhance the quality of life. However, the patients took a long time to become skilled in using the prosthesis. Four factors were related to better prosthesis function:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoidance of surgical soft palate defects",
"     </li>",
"     <li>",
"      Minimization of gingival and hard palate defects",
"     </li>",
"     <li>",
"      A mouth opening of more than 20 mm",
"     </li>",
"     <li>",
"      Preservation of as much natural teeth as possible",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a similar questionnaire study in 47 patients undergoing resection and prosthesis for maxillary defects, satisfactory functioning of the obturator prosthesis was the most important determinant of quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/28\">",
"     28",
"    </a>",
"    ]. The most significant predictors of obturator prosthesis functioning were the extent of resection of the soft palate (one third or less) and hard palate (one fourth or less).",
"   </p>",
"   <p>",
"    Individual determination and the capacity to adapt will always be critical towards successful outcome of prosthetic treatment. Other parameters, such as location and size of the defect, quality of the created surgical bed and closure, or other complications (such as trismus and mouth opening, xerostomia, mucositis), will also affect the prognosis of the prosthetic rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8919/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prosthetic rehabilitation of patients with hard palate defects due to resection of tumor involving the maxilla consists of placement of an obturator prosthesis, which serves to restore orofacial functions, including deglutition, control of secretions, mastication, and phonetics, and to aesthetically replace the missing orofacial structures.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial planning for patients about to undergo treatment for head and neck cancer should include consultation with a prosthodontist consisting of a complete orofacial exam and evaluation of existing dentoalveolar conditions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment planning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical considerations that may optimize prosthetic function include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Providing a band of keratinized palatal mucosa to cover the medial aspect of the exposed residual bony palate.",
"     </li>",
"     <li>",
"      A stable well-supported prosthesis that needs three separate contact points for anchoring; consideration should be given to maintaining strategically positioned teeth and osseous structures, including the zygomatico-temporal at the posterolateral aspect of the defect.",
"     </li>",
"     <li>",
"      Lining the inner surface of the intraoral defect with a split-thickness graft to provide a more tolerant surface to frictional forces.",
"     </li>",
"     <li>",
"      Removal of the nasal turbinates, the coronoid process of the mandible, and the soft palate, if less than one-third of its posterior aspect will remain after resection.",
"     </li>",
"     <li>",
"      Creation of a labioalveolar vestibule of adequate depth so that the surgical obturator prosthesis may contain a flange that extends into the vestibule, preventing undesirable fibrous attachment to the crest of the alveolar ridge. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Surgical considerations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are three stages of prosthodontic rehabilitation of an acquired hard palate defect:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Creation of an immediate, surgical obturator prosthesis.",
"     </li>",
"     <li>",
"      Insertion of a transitional obturator prosthesis a minimum of 7 to 10 days postoperatively.",
"     </li>",
"     <li>",
"      Fabrication of a definitive, removable obturator prosthesis once adequate healing has occurred and radiation therapy is completed (typically three to four months after treatment completion). This can include the use of dental implants to enhance stability and retention. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Prosthodontic rehabilitation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A well-functioning obturator prosthesis enhances the quality of life of maxillectomy patients. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/1\">",
"      Patton DW, Ali A, Davies R, Fardy MJ. Oral rehabilitation and quality of life following the treatment of oral cancer. Dent Update 1994; 21:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/2\">",
"      Usui H. [Evaluation of maxillary prosthesis for better QOL]. Nihon Jibiinkoka Gakkai Kaiho 1994; 97:1643.",
"     </a>",
"    </li>",
"    <li>",
"     The academy of prosthodontics. The glossary of prosthodontic terms, Mosby, St. Louis 1994.",
"    </li>",
"    <li>",
"     Curtis TA, Beumer J. Restoration of acquired hard palate defects: etiology, disability, and rehabilitation. In: Maxillofacial Rehabilitation; Prosthodontic and Surgical Considerations, Beumer J, Curtis TA, Marunick MT (Eds), Ishiyaku EuroAmerica, Inc, St. Louis 1996. p.225.",
"    </li>",
"    <li>",
"     Beumer J, Nishimura R, Roumanas E. Maxillary defects: Alterations at surgery which enhance the prosthetic prognosis. In: Proceedings of first International Congress on Maxillofacial Prosthetics, Zlotolow I, Esposito S, Beumer J (Eds), 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/6\">",
"      Desjardins RP. Obturator prosthesis design for acquired maxillary defects. J Prosthet Dent 1978; 39:424.",
"     </a>",
"    </li>",
"    <li>",
"     Bloomer HH, Hawk AM. Speech considerations: Speech disorders associated with ablative approaches to learning. In: Speech considerations: Speech disorders associated with ablative approaches to learning, ASHA, 1973. p.42.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/8\">",
"      Beumer J 3rd, Roumanas E, Nishimura R. Advances in osseointegrated implants for dental and facial rehabilitation following major head and neck surgery. Semin Surg Oncol 1995; 11:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/9\">",
"      Gary JJ, Donovan M, Garner FT, Faulk JE. Rehabilitation with calvarial bone grafts and osseointegrated implants after partial maxillary resection: a clinical report. J Prosthet Dent 1992; 67:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/10\">",
"      Lorant JA, Roumanas E, Nishimura R, et al. Restoration of oral function after maxillectomy with osseous integrated implant retained maxillary obturators. Am J Surg 1994; 168:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/11\">",
"      Kabcenell J, Silken D, Kraut R. Restoration of a total maxillectomy patient using endosseous implants. Int J Prosthodont 1992; 5:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/12\">",
"      Niimi A, Ueda M, Kaneda T. Maxillary obturator supported by osseointegrated implants placed in irradiated bone: report of cases. J Oral Maxillofac Surg 1993; 51:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/13\">",
"      Kov&aacute;cs AF. The fate of osseointegrated implants in patients following oral cancer surgery and mandibular reconstruction. Head Neck 2000; 22:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/14\">",
"      Panje WR, Hetherington HE, Toljanic J, et al. Bilateral maxillectomy and midfacial reconstruction. Ann Otol Rhinol Laryngol 1995; 104:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/15\">",
"      Sj&ouml;vall L, Lindqvist C, Hallikainen D. A new method of reconstruction in a patient undergoing bilateral total maxillectomy. Int J Oral Maxillofac Surg 1992; 21:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/16\">",
"      Juntunen K, Kullaa A, Lamberg MA, Virtaniemi J. A new application of a screw-plate for prosthetic reconstruction after bilateral total maxillectomy. Clin Oral Implants Res 1993; 4:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/17\">",
"      Toljanic JA, Zucuskie TG. Use of a palatal reservoir in denture patients with xerostomia. J Prosthet Dent 1984; 52:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/18\">",
"      Antoniou DV, Toljanic JA, Graham L. Obturator prosthesis retention for edentulous patients with large palatal defects: a clinical report. J Prosthet Dent 1996; 76:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/19\">",
"      Rahn AO, Goldman BM, Parr GR. Prosthodontic principles in surgical planning for maxillary and mandibular resection patients. J Prosthet Dent 1979; 42:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/20\">",
"      Ali A, Patton DW, Fardy MJ. Prosthodontic rehabilitation in the maxilla following treatment of oral cancer. Dent Update 1994; 21:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/21\">",
"      Curtis TA, Cantor R. The maxillofacial rehabilitation of President Grover Cleveland and Dr. Sigmund Freud. J Am Dent Assoc 1968; 76:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/22\">",
"      Didier M, Laccoureye O, Brasnu D, Vignon M. New surgical obturator prosthesis for hemimaxillectomy patients. J Prosthet Dent 1993; 69:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/23\">",
"      Kaplan P. Stabilization of an interim obturator prosthesis using a denture duplicator. J Prosthet Dent 1992; 67:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/24\">",
"      King GE, Chambers MS, Martin JW. Patient appointments during interim obturation: is it cost-effective? J Prosthodont 1995; 4:168.",
"     </a>",
"    </li>",
"    <li>",
"     Laney WR. Maxillofacial applications of removable partial prosthodontics. In: McCracken's Removable Partial Prosthodontics, McGivney GP, Castleberry DJ (Eds), The CV Mosby Co, St. Louis 1989. p.465.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/26\">",
"      Jardine SJ, Basker RM, Ralph JP. Problems in restorative dentistry: who copes with them? Br Dent J 1995; 178:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/27\">",
"      Martin JW, Austin JR, Chambers MS, et al. Postoperative care of the maxillectomy patient. ORL Head Neck Nurs 1994; 12:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8919/abstract/28\">",
"      Kornblith AB, Zlotolow IM, Gooen J, et al. Quality of life of maxillectomy patients using an obturator prosthesis. Head Neck 1996; 18:323.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3376 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_45_8919=[""].join("\n");
var outline_f8_45_8919=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT PLANNING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SURGICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Palatal mucosal incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Preservation of teeth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Preservation of disease-free osseous structures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Split-thickness skin graft",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Soft palate considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Elimination of nasal turbinates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Posterolateral support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vestibular depth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Implants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Removal of coronoid process of mandible",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PROSTHODONTIC REHABILITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Immediate (surgical) obturator prostheses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Transitional obturator prosthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Definitive (permanent) obturator prosthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39815?source=related_link\">",
"      Mandibular and palatal reconstruction in patients with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=related_link\">",
"      Oral toxicity associated with chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31545?source=related_link\">",
"      Speech and swallowing rehabilitation of the patient with head and neck cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_45_8920="Continuous nasal NPPV";
var content_f8_45_8920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Continuous nasal NPPV",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John R Bach, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_45_8920=[""].join("\n");
var outline_f8_45_8920=null;
var title_f8_45_8921="Surgical and endovascular repair of blunt thoracic aortic injury";
var content_f8_45_8921=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical and endovascular repair of blunt thoracic aortic injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/45/8921/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/45/8921/contributors\">",
"     David G Neschis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/45/8921/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/45/8921/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/45/8921/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/45/8921/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/45/8921/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/45/8921/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1081750594\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt aortic injury is a life-threatening condition that will require repair in most patients and is second only to head injury as a cause of death in injured patients. Only about 20 percent of individuals survive long enough following injury to be treated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The",
"    <strong>",
"    </strong>",
"    most significant advance in the past 50 years for the treatment of thoracic aortic disease is endovascular stent-grafting. Compared with other etiologies that are treated with thoracic endovascular stenting, such as thoracic aneurysm, patients with blunt aortic injury tend to be younger with anatomic features that can present challenges for the placement of endograft devices, which were not designed for this indication.",
"   </p>",
"   <p>",
"    The surgical and endovascular options for repair of the traumatic thoracic aortic disruption will be reviewed. The diagnosis and management of blunt thoracic aortic injury is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9609?source=see_link\">",
"     \"Blunt thoracic aortic injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13962151\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR AND TIMING OF REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic repair for blunt aortic injury is indicated for patients with injury Grades II, III, and IV. The diagnosis, grading and indications for repair, as well as timing of repair, are discussed elsewhere. Aortic repair is generally not indicated for patients with Type I injury (intima only), but may become necessary if the injury progresses. Aortic repair may be delayed in patients with a high surgical risk, due to comorbidities, challenging aortic anatomy, or coexistent injuries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9609?source=see_link&amp;anchor=H2669606#H2669606\">",
"     \"Blunt thoracic aortic injury\", section on 'Aortic injury grading'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9609?source=see_link&amp;anchor=H2669935#H2669935\">",
"     \"Blunt thoracic aortic injury\", section on 'Approach to management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13962182\">",
"    <span class=\"h1\">",
"     ENDOVASCULAR VERSUS OPEN SURGICAL REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <strong>",
"    </strong>",
"    most significant surgical advance in the past 50 years for the treatment of thoracic aortic disease is endovascular stent grafting. Although endovascular repair of the thoracic aorta is emerging as a preferred treatment option for other thoracic aortic pathologies, patients with blunt aortic injury have multiple considerations that determine the choice between open surgical and endovascular repair. These include the presence and type of associated injuries, anatomic issues such as the location of the injury and diameter of the aorta, the patient&rsquo;s life expectancy and likelihood of cooperation with long-term follow-up in the event of endovascular repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2093847239\">",
"    <span class=\"h2\">",
"     Comparative morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unlikely that randomized trials will ever be performed comparing open and endovascular repair for treatment of blunt aortic injury. Comparisons of the rates of major morbidity and mortality from retrospective case reviews and metaanalysis suggest a benefit for endovascular repair [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/4-9\">",
"     4-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Association for the Society on Trauma (AAST)-1 study evaluated 274 cases of blunt aortic injury from 50 trauma centers over a two-and-a-half-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/10\">",
"     10",
"    </a>",
"    ]. A variety of open surgical techniques were used and overall mortality was found to be 31 percent. Approximately 10 years later, the AAST-2 study found a modest reduction in mortality to 23.5 percent for patients undergoing open surgical repair [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/7\">",
"     7",
"    </a>",
"    ]. During that time period, thoracic endovascular grafting was introduced and mortality associated with it was significantly lower compared with open repair at 7.2 percent.",
"   </p>",
"   <p>",
"    Separate metaanalyses confirmed the trend identified in the AAST studies. The first analyzed 13 comparative studies and found a reduced risk of perioperative death (relative risk [RR] 0.61, 95% CI 0.46-0.80), and spinal cord ischemia (RR 0.34, 95% CI 0.16-0.74) for endovascular repair compared with open surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/11\">",
"     11",
"    </a>",
"    ]. A later systematic review compared the outcomes of 7768 patients, drawn from 27 retrospective studies and 112 case series, treated with endovascular or open repair, and in some cases, with no repair [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/5\">",
"     5",
"    </a>",
"    ]. Overall mortality was significantly lower for patients who underwent endovascular compared with open repair or no repair (9 versus 19 and 46 percent, respectively). Injury severity score correlated with mortality for open surgical repair, but not for endovascular repair. A review at the author&rsquo;s institution has identified similarly reduced mortality rates for endovascular repair, and also significantly shorter lengths of stay, less need for blood transfusion, and less need for postoperative tracheostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is worth noting that open surgical procedures in older case series have generally been performed immediately following identification of the aortic injury. More recently, this practice has been questioned with a trend toward managing patients with aortic injury who are hemodynamically stable conservatively with heart rate and blood pressure control initially. The aortic repair is delayed until the patient is physiologically optimized. Delayed surgical management has also been associated with decreased mortality rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9609?source=see_link&amp;anchor=H1759284759#H1759284759\">",
"     \"Blunt thoracic aortic injury\", section on 'Immediate versus delayed repair'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The long-term outcomes of thoracic endovascular repair for blunt aortic injury are not known. Thoracic endovascular grafts have not been optimally designed for the normal caliber aorta of younger patients. The aortic diameter of young adults is narrower than in older adults, and those with aneurysmal disease. Younger patients also tend to have a more acutely angulated aortic arch. Endovascular grafts deployed at the aortic arch may appose poorly to the inner curve of the arch, predisposing to endoleak from graft buckling or infolding. Thus, as with any endovascular aortic repair, all patients who undergo endovascular repair are required to participate in ongoing surveillance for the duration of their life to detect endoleak. Reintervention following endovascular repair is required in up to 20 percent of patients. (See",
"    <a class=\"local\" href=\"#H255247576\">",
"     'Endograft-related complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2093847775\">",
"    <span class=\"h2\">",
"     Choice of repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of these many issues, the choice between open and endovascular thoracic aortic repair should be individualized, taking into account the patient&rsquo;s specific injuries, age, anatomy, and other comorbidities. Endovascular repair is likely the preferred option for many patients, but open surgery, which is durable and does not require ongoing graft surveillance may be a better option for patients with an acceptable surgical risk, and is the only option for patients with anatomic features that preclude endovascular repair. (See",
"    <a class=\"local\" href=\"#H2073945\">",
"     'Anatomic criteria for endograft repair'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Clinical and anatomic features that favor endovascular repair include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple severe injuries",
"     </li>",
"     <li>",
"      Severe right chest or lung injuries; the patient may not tolerate one-lung ventilation, which is required for open surgery",
"     </li>",
"     <li>",
"      Multiple medical comorbidities",
"     </li>",
"     <li>",
"      Limited life-expectancy",
"     </li>",
"     <li>",
"      Lesion confined to the descending thoracic aorta",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical and anatomic features that favor open surgical repair include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Younger age",
"     </li>",
"     <li>",
"      Patient unwilling or unable to comply with lifelong graft surveillance",
"     </li>",
"     <li>",
"      Lesion involving the ascending aorta or aortic arch",
"     </li>",
"     <li>",
"      Anatomic features that are unsuitable for endovascular repair (see",
"      <a class=\"local\" href=\"#H2073945\">",
"       'Anatomic criteria for endograft repair'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2073989\">",
"    <span class=\"h3\">",
"     Recommendations of others",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Society of Vascular Surgery practice guidelines for repair of traumatic aortic injury make a weak recommendation for endovascular repair [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/14\">",
"     14",
"    </a>",
"    ]. A higher value is placed on preventing mortality and morbidity such as spinal cord ischemia, compared with endograft complications that lead to reintervention and uncertain long-term outcomes. In general, we agree with this recommendation; however, patients may be more suited for one approach or another depending on the factors discussed above, and local institutional resources.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1081750615\">",
"    <span class=\"h1\">",
"     ENDOVASCULAR REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic endovascular repair was first described for the treatment of abdominal aortic aneurysm in 1991 and has been extended to the treatment of blunt aortic injury and other thoracic aortic pathologies within 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The number of patients treated with endovascular repair of blunt traumatic injuries has increased dramatically. In the AAST-1 study, stent graft repair was selected in 65 percent of cases of aortic trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/7,10\">",
"     7,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endovascular repair for blunt thoracic aortic injury is performed in a similar manner to the endovascular repair of thoracic aortic aneurysm, which is described in detail elsewhere. Technical success rates for blunt aortic injury vary widely, ranging from 10 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37240?source=see_link\">",
"     \"Thoracic endovascular aneurysm repair\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The information provided below highlights differences in thoracic endograft placement for grafts placed in normal caliber aortas for a variety of thoracic aortic pathologies, along with specific considerations in patients with thoracic aortic injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255247669\">",
"    <span class=\"h2\">",
"     Endografts and sizing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular repair of blunt thoracic injury is accomplished using a fabric covered stent termed an endograft or stent-graft. Four stent-graft systems for thoracic aortic repair are available for use in the United States and are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      TAG and Conformable TAG graft",
"     </li>",
"     <li>",
"      Zenith TX2",
"     </li>",
"     <li>",
"      Talent Thoracic Stent-Graft System",
"     </li>",
"     <li>",
"      Valiant Thoracic Stent-Graft System",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The essential features of these devices, and studies demonstrating their safety and efficacy, are discussed in detail elsewhere. A number of investigational devices are in early phases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39560?source=see_link\">",
"     \"Endovascular devices for thoracic aortic repair\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to note that the thoracic endograft devices were originally designed for the treatment of nonruptured aneurysms of the thoracic aorta. For the treatment of nonaneurysmal pathologies, each of these devices has technical advantages and disadvantages, and all are associated with technical success rates approaching 100 percent when used to treat focal lesions located within the descending portion of a non-tortuous thoracic aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. However, none of these devices are ideally suited to the narrow, acutely-angled aortic arch typical of the younger patient who presents with blunt aortic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Narrow thoracic aortas (&le;17.5 mm) cannot be accommodated by any of the available thoracic endograft devices with the appropriate degree of over-sizing to ensure proximal fixation. In one study, the average aortic diameter in patients with blunt aortic injury was about 23 mm with a range of 19 to 30 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/12\">",
"     12",
"    </a>",
"    ]. A next generation device, the Conformable TAG graft (CTAG), has been approved in the United States for the treatment of blunt aortic injury, and was designed to conform to smaller, more tortuous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tapered thoracic aortic anatomy to allow treatment of nonaneurysmal pathologies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/5\">",
"     5",
"    </a>",
"    ]. The CTAG is available in a minimal 21 mm diameter, which can accommodate an aorta that is 17.5 mm with 20 percent over-sizing [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative approach uses abdominal aortic devices [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/12,23\">",
"     12,23",
"    </a>",
"    ]. However, these devices are shorter in length, requiring more than one device for adequate coverage, and the delivery system is a shorter length. As with the thoracic endograft devices, none of the abdominal devices are suited to the tight angulation of the aortic arch in the younger patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2073945\">",
"    <span class=\"h2\">",
"     Anatomic criteria for endograft repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following criteria are mandatory for thoracic endograft placement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aortic diameter at proximal landing zone &ge;17.5 mm",
"     </li>",
"     <li>",
"      Adequate proximal and distal landing zones (&ge;2 cm in",
"      <sup>",
"      </sup>",
"      length)",
"     </li>",
"     <li>",
"      Minimal calcification at the",
"      <sup>",
"      </sup>",
"      fixation sites",
"     </li>",
"     <li>",
"      Focal aortic lesion",
"     </li>",
"     <li>",
"      Location in the descending thoracic aorta",
"     </li>",
"     <li>",
"      No significant",
"      <sup>",
"      </sup>",
"      tortuosity of the thoracic aorta",
"     </li>",
"     <li>",
"      No intraluminal thrombus",
"     </li>",
"     <li>",
"      Adequate diameter and quality of access vessels (sheath size depends upon the graft chosen)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170894103\">",
"    <span class=\"h2\">",
"     Spinal drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for specific measures to protect the spinal cord are similar to thoracic endovascular repair for aneurysmal disease. However, for blunt aortic injury occurring in the proximal portion of the descending thoracic aorta, spinal drainage is generally not needed. Spinal fluid drainage should be considered if the entire thoracic aorta requires endograft coverage, there has been a preexisting repair of the infrarenal aorta, or the area of coverage will include the distal third of the thoracic aorta. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37240?source=see_link\">",
"     \"Thoracic endovascular aneurysm repair\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255247707\">",
"    <span class=\"h2\">",
"     Device placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should be placed in a supine position on a bean bag, then prepared and draped. On occasion, conversion to an open thoracotomy may be needed and preemptive placement on a bean bag (used for thoracotomy positioning) minimizes the delay. Arterial cutdown of the common femoral artery is usually performed, though percutaneous access has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Once the common femoral artery is exposed, the access sheath is placed into the common femoral artery and a guidewire is advanced through the sheath into the proximal aorta.",
"   </p>",
"   <p>",
"    Aortography can be performed via a catheter placed percutaneously through the contralateral groin (or brachial artery) to confirm the anatomy and define the landing zones for the device. The device is positioned across the area of pathology by advancing it over a stiff guidewire. The position of the device is confirmed with repeat aortography. Prior to device deployment, the patient&rsquo;s blood pressure should be lowered to lessen the arterial impulse and minimize the potential for misplacement during deployment. The device is then deployed, thus excluding the perforated site from the circulation. A completion aortogram should be performed to confirm patency of the endograft and successful exclusion of the area of disruption (ie, no endoleaks). The guidewires and introducer sheaths are removed and the arteriotomies are repaired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255247739\">",
"    <span class=\"h3\">",
"     Heparinization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic anticoagulation is typically used during the placement of endovascular grafts to reduce the risk of thrombus formation within the thoracic aorta and around the sheath site, which could lead to distal embolization and possibly stroke. However, in patients with traumatic aortic injury, significant associated injuries, such as intracranial hemorrhage or splenic injury, may contraindicate anticoagulation. Under these circumstances, endovascular repair of the thoracic aorta without the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has been used without adverse consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. For patients with traumatic aortic injuries and a contraindication to heparin, particularly if the aortic injury appears to be in an anatomically favorable location, we proceed with endograft repair without systemic heparinization. This approach may also allow earlier intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13963500\">",
"    <span class=\"h3\">",
"     Subclavian coverage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positioning the top of the endograft proximal to the origin of the left subclavian artery can lead to poor apposition of the graft along the inside curvature of the aortic arch, particularly in younger patients who have a narrower aorta. This may increase the risk of endoleak or endograft collapse. (See",
"    <a class=\"local\" href=\"#H255247576\">",
"     'Endograft-related complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An adequate proximal landing zone may require coverage of the left subclavian artery, particularly in patients with blunt aortic injury, for whom the injury is typically located at the level of the aortic isthmus. In our experience, complete or partial coverage of the origin of the left subclavian artery is needed in about 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/12\">",
"     12",
"    </a>",
"    ]. Although coverage of the subclavian artery origin is usually well tolerated, symptoms of vertebrobasilar insufficiency can develop in patients with a dominant left vertebral artery, and coronary steal syndrome can develop in patients who have a left internal mammary coronary bypass graft (",
"    <a class=\"graphic graphic_figure graphicRef76733 \" href=\"UTD.htm?39/22/40288\">",
"     figure 1",
"    </a>",
"    ). These patients may benefit from extraanatomic bypass (carotid subclavian bypass) prior to coverage of the left subclavian with the stent-graft [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37240?source=see_link\">",
"     \"Thoracic endovascular aneurysm repair\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13963523\">",
"    <span class=\"h2\">",
"     Postoperative care and follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following endovascular repair, the patient should be observed typically on a monitored floor. The access site should be checked for signs of bleeding, and distal pulses serially examined. Once the endograft is in place, the heart rate and blood pressure can be maintained in a normal range. Neurologic assessment should be performed at routine intervals in the first 24 hours to evaluate for neurologic complications of thoracic aortic repair such as paraplegia or stroke. &nbsp;",
"   </p>",
"   <p>",
"    If the patient has no other associated injuries or medical conditions requiring treatment, the patient can be discharged typically within a couple of days of the procedure and normal activities can typically be resumed within a couple of weeks. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2093837510\">",
"    <span class=\"h3\">",
"     Graft surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal program for thoracic endograft surveillance is still being defined. Routine surveillance is typically performed annually with contrast-enhanced computed tomography (CT) of the chest.",
"   </p>",
"   <p>",
"    Patients who have undergone endovascular repair of the thoracic aorta require lifelong graft surveillance. The need for ongoing follow-up is important when selecting patients for endovascular repair, particularly in the trauma population and, for some patients, an inability to comply with graft surveillance may be a deciding factor favoring open surgical repair. (See",
"    <a class=\"local\" href=\"#H2093847775\">",
"     'Choice of repair'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Over the course of time, radiation exposure may become a significant issue, particularly in young patients who will be subjected to numerous CT scans over their lifetime. For patients who have demonstrated stable-appearing endograft repairs, we lengthen the interval between studies to reduce the risks associated with repeated radiation exposure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170892394\">",
"    <span class=\"h1\">",
"     OPEN SURGICAL REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with blunt thoracic aortic injury are typically younger with no significant preexisting medical comorbidities; however, coexisting injuries, particularly head injury and lung injury, as well as other medical issues may influence the choice and timing of repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9609?source=see_link&amp;anchor=H1759284759#H1759284759\">",
"     \"Blunt thoracic aortic injury\", section on 'Immediate versus delayed repair'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Open repair of traumatic aortic injury is similar to open repair of thoracic aortic aneurysm with some notable exceptions which are discussed below. Open repair of thoracic aortic aneurysm is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/7/10361?source=see_link\">",
"     \"Management and outcome of thoracic aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Open surgical repair of the thoracic aorta is performed under general anesthesia using a double lumen tube. One-lung ventilation allows collapse of the left lung and facilitates access to the aorta. It is important to note that patients with severe associated right chest or lung injuries may not tolerate one-lung ventilation. Delayed repair or endovascular repair may be warranted.",
"   </p>",
"   <p>",
"    The extent of the thoracotomy incision is based upon the location of the pathology. As examples, in blunt aortic injury, the aortic disruption usually occurs at the aortic isthmus, and thus, a fourth intercostal space thoracotomy incision should be performed. More extensive involvement may require sternotomy or thoracoabdominal exposure.",
"   </p>",
"   <p>",
"    Once the chest is entered, the site of pathology is identified and any bleeding should be controlled with direct pressure while an aortic clamp is placed just distal to the left subclavian artery. If the aortic disruption is in close proximity to the left subclavian artery, the clamp will need to be placed between the left common carotid artery and the left subclavian artery.",
"   </p>",
"   <p>",
"    In some cases, such as a small traumatic tear, the aorta can be repaired primarily; however, most patients require the placement of an interposition graft (eg, Dacron). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170892422\">",
"    <span class=\"h2\">",
"     Spinal cord perfusion techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clamping the thoracic aorta compromises the blood supply to the spinal cord. Active perfusion of the distal aorta, which is a source of flow to the spinal arteries, has reduced the incidence of paraplegia associated with repair of blunt thoracic aortic injury to about 2 percent, with some centers reporting no spinal cord complications [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/28-33\">",
"     28-33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H170894764\">",
"     'Spinal cord ischemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the early experience of open thoracic aortic repair for blunt thoracic aortic injury, most procedures were performed with a clamp-and-sew technique. However, even a short cross clamp time (&lt;30 minutes) did not prevent spinal cord ischemia and neurologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. A metaanalysis reported a 19 percent incidence of paraplegia, and mortality of 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/28\">",
"     28",
"    </a>",
"    ]. An older technique, passive perfusion, in which a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -bonded shunt is placed to divert blood from the proximal aorta above the site of clamping to the distal aorta below the site of the clamping, has been supplanted by active perfusion techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Active perfusion can be achieved using one of two techniques:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left atrial-femoral bypass &ndash; Left atrial-femoral bypass is accomplished by placing a cannula into the left atrium (or pulmonary vein). The oxygenated blood is pumped and delivered to the distal aorta via a cannula placed into the left common femoral artery. This simple circuit can be performed with a relatively small dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (about 5000 units). One of the disadvantages of this technique is that it relies on oxygenation of the blood in a patient using a single lung. The level of oxygenation may not be sufficient in patients with concomitant pulmonary contusion.",
"     </li>",
"     <li>",
"      Femoral venous-to-femoral arterial cardiopulmonary bypass &ndash; An alternative technique places a cannula in the femoral vein and advanced to the right atrium. A second cannula is placed in the femoral artery. This technique is known as femoral venous-to-femoral arterial cardiopulmonary bypass (venoarterial bypass). With this technique, deoxygenated blood is drawn from the cannula in the right atrium and circulated through a cardiopulmonary bypass machine to oxygenate the blood before returning it to the patient via the femoral artery. Advantages of the venoarterial bypass include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It allows simultaneous cooling of the patient, which may augment spinal cord protection.",
"     </li>",
"     <li>",
"      Oxygenation of the blood is independent of the lung, which is preferred in patients with concomitant lung injury [",
"      <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Systemic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      administration can be minimized by using heparin-coated tubing [",
"      <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a 30 year retrospective review, paraplegia did not occur in 73 patients who underwent repair of the thoracic aorta for traumatic injury using venoarterial bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13962198\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main complications associated with open and endovascular repair of the thoracic aorta for blunt aortic injury include access complications, stroke, spinal cord ischemia, and endograft-related complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170894764\">",
"    <span class=\"h2\">",
"     Spinal cord ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord ischemia may result in paraparesis or paraplegia. Although the incidence of spinal cord complications has steadily diminished with the increased use of active perfusion techniques, paraplegia remains a significant concern when open repair is used to repair the thoracic aorta. The incidence of paraplegia ranges between 0 and 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/5,7,8\">",
"     5,7,8",
"    </a>",
"    ]. The American Association for the Society on Trauma AAST-2 study reported an overall reduction in the incidence of paraplegia from 8.7 to 1.6 percent (open and endovascular repair). This reduction was correlated to a 20 percent increase in the use of spinal cord perfusion techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/8\">",
"     8",
"    </a>",
"    ]. The incidence of paraplegia associated with endovascular repair decreased to 0.8 percent over that same time period. In a systematic review that included 7768 patients undergoing open surgical or endovascular repair for thoracic aortic injury, the risk of spinal cord ischemia was significantly lower for endovascular (3 versus 9 percent) versus open repair [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108701577\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative stroke is a potentially devastating complication of repair of blunt aortic injury. The risk of stroke is higher for repair of aortic injury that is proximal to the origin of the left subclavian artery.",
"   </p>",
"   <p>",
"    In a review of five investigational endovascular device trials that included 60 patients with blunt aortic injury, the incidence of cerebrovascular events (excluding transient ischemic attack) was 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/37\">",
"     37",
"    </a>",
"    ]. An earlier systematic review of 33 retrospective studies included 370 patients who underwent endovascular repair and 329 open repairs for blunt aortic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/11\">",
"     11",
"    </a>",
"    ]. Stroke occurred in 1 percent of patients following endovascular repair and 4.5 percent of patients undergoing open surgical repair [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/11\">",
"     11",
"    </a>",
"    ]. The details of the injuries treated were not provided in the review. Other reviews of thoracic endovascular repair performed for assorted thoracic aortic pathologies report stroke rates ranging from 0 to 4.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/38-41\">",
"     38-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In observational studies, coverage of the left subclavian artery during endograft placement increases the reported incidence of stroke during thoracic endovascular aneurysm repair [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. In one of these studies, the incidence of stroke increased with subclavian coverage both with and without left subclavian revascularization compared with no left subclavian coverage (with revascularization: 4.7 versus 2.7 percent; without revascularization: 4.1 versus 2.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/43\">",
"     43",
"    </a>",
"    ]. A similar comparison has not been performed for blunt aortic injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255247576\">",
"    <span class=\"h2\">",
"     Endograft-related complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular repair of the thoracic aorta is associated with a 20 percent incidence of graft-related complications including technical failure, endoleak, stent graft collapse, iliac artery injury, and other device-related failures (eg, metal stent penetration, device component disconnect) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/12,45\">",
"     12,45",
"    </a>",
"    ]. Improvements in the design of thoracic endovascular grafts that take into account the anatomy of the nonaneurysmal aorta, particularly in younger patients, should help reduce the incidence of device-related complications.",
"   </p>",
"   <p>",
"    Device complications can be related to endograft under-sizing, excessive over-sizing, or related to device deployment. As an example, positioning the endograft with its leading edge perpendicular to blood flow in the transverse aortic arch can lead to device collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. Efforts to avoid over-sizing can lead to inappropriate under-sizing. Under-sizing may also be the result of an underestimation of the diameter of the aorta in the face of systemic hypotension. The highly elastic thoracic aorta recoils, leading to measurements on computed tomography (CT) that can underestimate the true aortic diameter at normal blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/49\">",
"     49",
"    </a>",
"    ]. Intravascular ultrasound during endovascular repair may be helpful for confirming aortic diameter in real-time as the patient is being resuscitated; however, availability of this modality is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/10,50,51\">",
"     10,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In spite of the short-term benefits of decreased mortality and paraplegia, the long-term durability of thoracic endograft devices for the repair of nonaneurysmal pathologies is unknown. Many patients with blunt aortic injury are young, and it is unknown how the endograft will respond to normal aging. The thoracic aorta tends to enlarge with age, but it is unknown whether or not the aorta adjacent the endograft will enlarge and result in endoleak.",
"   </p>",
"   <p>",
"    Endoleak in the nonaneurysmal aorta is defined as persistent flow around the graft in the native aorta following endovascular repair. In the AAST-2 study of blunt aortic injury, the incidence of endoleak (mostly type I) was 14.4 percent, of which one-third subsequently required open repair [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/7\">",
"     7",
"    </a>",
"    ]. Our experience has been similar. In 43 consecutive cases, six endoleaks occurred with three patients requiring open surgical repair and endograft explantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/45/8921/abstract/12\">",
"     12",
"    </a>",
"    ]. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37240?source=see_link\">",
"     \"Thoracic endovascular aneurysm repair\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13964233\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blunt thoracic aortic injury is a life-threatening condition that requires repair in the majority of patients. Only about 20 percent of individuals survive long enough following injury to be treated. (See",
"      <a class=\"local\" href=\"#H1081750594\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13962151\">",
"       'Indications for and timing of repair'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9609?source=see_link&amp;anchor=H2669935#H2669935\">",
"       \"Blunt thoracic aortic injury\", section on 'Approach to management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Endovascular repair of blunt thoracic injury is accomplished using a fabric covered stent termed an endograft or stent-graft. Thoracic endograft devices were originally designed for the treatment of nonruptured aneurysms of the thoracic aorta. None of the endograft devices are ideally suited to the narrow, acutely-angled aortic arch of the typically younger patient who presents with blunt aortic injury. When used to to treat focal lesions located within the descending portion of a non-tortuous thoracic aorta, technical success rates approach 100 percent. &nbsp;(See",
"      <a class=\"local\" href=\"#H255247669\">",
"       'Endografts and sizing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39560?source=see_link\">",
"       \"Endovascular devices for thoracic aortic repair\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Narrow thoracic aortas (&le;17.5 mm) cannot be accommodated by any of the available thoracic endograft devices with the appropriate degree of over-sizing needed to ensure proximal fixation. A next generation device, the Conformable TAG graft (CTAG), which was designed to conform to smaller, more tortuous",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tapered thoracic aortic anatomy, has been approved in the United States specifically for the treatment of blunt aortic injury. The CTAG is available in a minimal 21 mm diameter, which can accommodate an aorta that is 17.5 mm with 20 percent over-sizing. (See",
"      <a class=\"local\" href=\"#H255247669\">",
"       'Endografts and sizing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with blunt aortic injury have multiple issues that must be considered when determining whether open surgical or endovascular repair of the thoracic aorta is more appropriate. These include the presence and type of associated injuries, anatomic features such as the location of the injury and diameter of the aorta, the patient&rsquo;s life expectancy, and the likelihood of compliance with long-term follow-up in the event of endovascular repair. (See",
"      <a class=\"local\" href=\"#H13962182\">",
"       'Endovascular versus open surgical repair'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical and anatomic features that favor endovascular repair include:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Multiple associated severe injuries",
"     </li>",
"     <li>",
"      Severe right chest or lung injuries. The patient may not tolerate one-lung ventilation, which is required for open surgery",
"     </li>",
"     <li>",
"      Multiple medical comorbidities",
"     </li>",
"     <li>",
"      Limited life-expectancy",
"     </li>",
"     <li>",
"      Lesion confined to the descending thoracic aorta",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical and anatomic features that favor open surgical repair include:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Younger age",
"     </li>",
"     <li>",
"      Patient unwilling or unable to comply with lifelong graft surveillance",
"     </li>",
"     <li>",
"      Lesion involving the ascending aorta or aortic arch",
"     </li>",
"     <li>",
"      Anatomic features that are unsuitable for endovascular repair (see",
"      <a class=\"local\" href=\"#H2073945\">",
"       'Anatomic criteria for endograft repair'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endovascular repair of the thoracic aorta is emerging as a preferred repair technique for other thoracic aortic pathologies. For blunt aortic injury, endovascular repair is associated with a significantly decreased mortality and a lower incidence of spinal cord ischemia compared with open surgical repair. However, the long-term outcomes of thoracic endovascular repair, particularly in younger patients, are not known. Reintervention following endovascular repair is needed in up to 20 percent of patients, and thus, patients who undergo endovascular repair require lifetime surveillance, which exposes the patient to the ongoing risks of repeated radiation. (See",
"      <a class=\"local\" href=\"#H13962182\">",
"       'Endovascular versus open surgical repair'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H255247576\">",
"       'Endograft-related complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major complications associated with both open and endovascular repair of the thoracic aorta for blunt aortic injury are spinal cord ischemia and stroke. The risk of spinal cord ischemia is lower for endovascular compared with open repair of blunt thoracic aortic injury. Comparative stroke rates are less well defined. For endovascular repair, endograft complications occur in about 20 percent of patients and include access-related vascular injury, technical failure in placement, and other device-related problems such as endoleak, stent-graft collapse, stent-graft migration, and device component disconnect among others. (See",
"      <a class=\"local\" href=\"#H13962198\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/1\">",
"      Sevitt S. The mechanisms of traumatic rupture of the thoracic aorta. Br J Surg 1977; 64:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/2\">",
"      Smith RS, Chang FC. Traumatic rupture of the aorta: still a lethal injury. Am J Surg 1986; 152:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/3\">",
"      Schulman CI, Carvajal D, Lopez PP, et al. Incidence and crash mechanisms of aortic injury during the past decade. J Trauma 2007; 62:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/4\">",
"      Neschis DG, Scalea TM, Flinn WR, Griffith BP. Blunt aortic injury. N Engl J Med 2008; 359:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/5\">",
"      Murad MH, Rizvi AZ, Malgor R, et al. Comparative effectiveness of the treatments for thoracic aortic transection [corrected]. J Vasc Surg 2011; 53:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/6\">",
"      Xenos ES, Abedi NN, Davenport DL, et al. Meta-analysis of endovascular vs open repair for traumatic descending thoracic aortic rupture. J Vasc Surg 2008; 48:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/7\">",
"      Demetriades D, Velmahos GC, Scalea TM, et al. Operative repair or endovascular stent graft in blunt traumatic thoracic aortic injuries: results of an American Association for the Surgery of Trauma Multicenter Study. J Trauma 2008; 64:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/8\">",
"      Demetriades D, Velmahos GC, Scalea TM, et al. Diagnosis and treatment of blunt thoracic aortic injuries: changing perspectives. J Trauma 2008; 64:1415.",
"     </a>",
"    </li>",
"    <li>",
"     TEVAR using the redesigned TAG device (CTAG) for Traumatic Aortic Transection: A non-randomized multicenter trial. file://scvs.org/symposium/abstracts/2012/12.cgi (Accessed on January 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/10\">",
"      Fabian TC, Richardson JD, Croce MA, et al. Prospective study of blunt aortic injury: Multicenter Trial of the American Association for the Surgery of Trauma. J Trauma 1997; 42:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/11\">",
"      Tang GL, Tehrani HY, Usman A, et al. Reduced mortality, paraplegia, and stroke with stent graft repair of blunt aortic transections: a modern meta-analysis. J Vasc Surg 2008; 47:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/12\">",
"      Neschis DG, Moainie S, Flinn WR, et al. Endograft repair of traumatic aortic injury-a technique in evolution: a single institution's experience. Ann Surg 2009; 250:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/13\">",
"      Moainie SL, Neschis DG, Gammie JS, et al. Endovascular stenting for traumatic aortic injury: an emerging new standard of care. Ann Thorac Surg 2008; 85:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/14\">",
"      Lee WA, Matsumura JS, Mitchell RS, et al. Endovascular repair of traumatic thoracic aortic injury: clinical practice guidelines of the Society for Vascular Surgery. J Vasc Surg 2011; 53:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/15\">",
"      Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft implantation for abdominal aortic aneurysms. Ann Vasc Surg 1991; 5:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/16\">",
"      Volodos NL, Karpovich IP, Troyan VI, et al. Clinical experience of the use of self-fixing synthetic prostheses for remote endoprosthetics of the thoracic and the abdominal aorta and iliac arteries through the femoral artery and as intraoperative endoprosthesis for aorta reconstruction. Vasa Suppl 1991; 33:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/17\">",
"      Semba CP, Kato N, Kee ST, et al. Acute rupture of the descending thoracic aorta: repair with use of endovascular stent-grafts. J Vasc Interv Radiol 1997; 8:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/18\">",
"      Mitchell ME, Rushton FW Jr, Boland AB, et al. Emergency procedures on the descending thoracic aorta in the endovascular era. J Vasc Surg 2011; 54:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/19\">",
"      D'Souza S, Duncan A, Aguila F, et al. TEVAR for non-aneurysmal thoracic aortic pathology. Catheter Cardiovasc Interv 2009; 74:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/20\">",
"      K&ouml;lbel T, Dias N, Resch T, et al. In situ bending of thoracic stent grafts: clinical application of a novel technique to improve conformance to the aortic arch. J Vasc Surg 2009; 49:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/21\">",
"      Torsello GB, Torsello GF, Osada N, et al. Midterm results from the TRAVIATA registry: treatment of thoracic aortic disease with the valiant stent graft. J Endovasc Ther 2010; 17:137.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.goremedical.com/contentTypeDetail.jsp?action=contentDetail&amp;N=8083 8239&amp;contenttype=8327&amp;R=1276629378975 (Accessed on March 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/23\">",
"      Peterson BG, Longo GM, Matsumura JS, et al. Endovascular repair of thoracic aortic pathology with custom-made devices. Surgery 2005; 138:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/24\">",
"      Peterson BG, Matsumura JS, Morasch MD, et al. Percutaneous endovascular repair of blunt thoracic aortic transection. J Trauma 2005; 59:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/25\">",
"      Lee WA, Brown MP, Nelson PR, et al. Midterm outcomes of femoral arteries after percutaneous endovascular aortic repair using the Preclose technique. J Vasc Surg 2008; 47:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/26\">",
"      Lachat M, Pfammatter T, Witzke H, et al. Acute traumatic aortic rupture: early stent-graft repair. Eur J Cardiothorac Surg 2002; 21:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/27\">",
"      Hoornweg LL, Dinkelman MK, Goslings JC, et al. Endovascular management of traumatic ruptures of the thoracic aorta: a retrospective multicenter analysis of 28 cases in The Netherlands. J Vasc Surg 2006; 43:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/28\">",
"      von Oppell UO, Dunne TT, De Groot MK, Zilla P. Traumatic aortic rupture: twenty-year metaanalysis of mortality and risk of paraplegia. Ann Thorac Surg 1994; 58:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/29\">",
"      Szwerc MF, Benckart DH, Lin JC, et al. Recent clinical experience with left heart bypass using a centrifugal pump for repair of traumatic aortic transection. Ann Surg 1999; 230:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/30\">",
"      Moore EE, Burch JM, Moore JB. Repair of the torn descending thoracic aorta using the centrifugal pump for partial left heart bypass. Ann Surg 2004; 240:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/31\">",
"      Attar S, Cardarelli MG, Downing SW, et al. Traumatic aortic rupture: recent outcome with regard to neurologic deficit. Ann Thorac Surg 1999; 67:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/32\">",
"      Gammie JS, Shah AS, Hattler BG, et al. Traumatic aortic rupture: diagnosis and management. Ann Thorac Surg 1998; 66:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/33\">",
"      Kodali S, Jamieson WR, Leia-Stephens M, et al. Traumatic rupture of the thoracic aorta. A 20-year review: 1969-1989. Circulation 1991; 84:III40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/34\">",
"      Katz NM, Blackstone EH, Kirklin JW, Karp RB. Incremental risk factors for spinal cord injury following operation for acute traumatic aortic transection. J Thorac Cardiovasc Surg 1981; 81:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/35\">",
"      Guvendik L, Davis NR, Starr A. Repair of traumatic aortic transection: a management protocol and review of twenty-one patients. Thorac Cardiovasc Surg 1988; 36:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/36\">",
"      Cardarelli MG, McLaughlin JS, Downing SW, et al. Management of traumatic aortic rupture: a 30-year experience. Ann Surg 2002; 236:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/37\">",
"      Dake MD, White RA, Diethrich EB, et al. Report on endograft management of traumatic thoracic aortic transections at 30 days and 1 year from a multidisciplinary subcommittee of the Society for Vascular Surgery Outcomes Committee. J Vasc Surg 2011; 53:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/38\">",
"      Lee WA, Daniels MJ, Beaver TM, et al. Late outcomes of a single-center experience of 400 consecutive thoracic endovascular aortic repairs. Circulation 2011; 123:2938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/39\">",
"      Kaya A, Heijmen RH, Overtoom TT, et al. Thoracic stent grafting for acute aortic pathology. Ann Thorac Surg 2006; 82:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/40\">",
"      Wheatley GH 3rd, Gurbuz AT, Rodriguez-Lopez JA, et al. Midterm outcome in 158 consecutive Gore TAG thoracic endoprostheses: single center experience. Ann Thorac Surg 2006; 81:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/41\">",
"      Orford VP, Atkinson NR, Thomson K, et al. Blunt traumatic aortic transection: the endovascular experience. Ann Thorac Surg 2003; 75:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/42\">",
"      Clough RE, Modarai B, Topple JA, et al. Predictors of stroke and paraplegia in thoracic aortic endovascular intervention. Eur J Vasc Endovasc Surg 2011; 41:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/43\">",
"      Cooper DG, Walsh SR, Sadat U, et al. Neurological complications after left subclavian artery coverage during thoracic endovascular aortic repair: a systematic review and meta-analysis. J Vasc Surg 2009; 49:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/44\">",
"      Chung J, Kasirajan K, Veeraswamy RK, et al. Left subclavian artery coverage during thoracic endovascular aortic repair and risk of perioperative stroke or death. J Vasc Surg 2011; 54:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/45\">",
"      Idu MM, Reekers JA, Balm R, et al. Collapse of a stent-graft following treatment of a traumatic thoracic aortic rupture. J Endovasc Ther 2005; 12:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/46\">",
"      Steinbauer MG, Stehr A, Pfister K, et al. Endovascular repair of proximal endograft collapse after treatment for thoracic aortic disease. J Vasc Surg 2006; 43:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/47\">",
"      Neschis DG, Moaine S, Gutta R, et al. Twenty consecutive cases of endograft repair of traumatic aortic disruption: lessons learned. J Vasc Surg 2007; 45:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/48\">",
"      Tadros RO, Lipsitz EC, Chaer RA, et al. A multicenter experience of the management of collapsed thoracic endografts. J Vasc Surg 2011; 53:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/49\">",
"      van Prehn J, van Herwaarden JA, Muhs BE, et al. Difficulties with endograft sizing in a patient with traumatic rupture of the thoracic aorta: the possible influence of hypovolemic shock. J Vasc Surg 2008; 47:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/50\">",
"      Malhotra AK, Fabian TC, Croce MA, et al. Minimal aortic injury: a lesion associated with advancing diagnostic techniques. J Trauma 2001; 51:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/45/8921/abstract/51\">",
"      Gavelli G, Canini R, Bertaccini P, et al. Traumatic injuries: imaging of thoracic injuries. Eur Radiol 2002; 12:1273.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15185 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_45_8921=[""].join("\n");
var outline_f8_45_8921=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13964233\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1081750594\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13962151\">",
"      INDICATIONS FOR AND TIMING OF REPAIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13962182\">",
"      ENDOVASCULAR VERSUS OPEN SURGICAL REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2093847239\">",
"      Comparative morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2093847775\">",
"      Choice of repair",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2073989\">",
"      - Recommendations of others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1081750615\">",
"      ENDOVASCULAR REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H255247669\">",
"      Endografts and sizing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2073945\">",
"      Anatomic criteria for endograft repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170894103\">",
"      Spinal drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H255247707\">",
"      Device placement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H255247739\">",
"      - Heparinization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13963500\">",
"      - Subclavian coverage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13963523\">",
"      Postoperative care and follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2093837510\">",
"      - Graft surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H170892394\">",
"      OPEN SURGICAL REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170892422\">",
"      Spinal cord perfusion techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13962198\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170894764\">",
"      Spinal cord ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108701577\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H255247576\">",
"      Endograft-related complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13964233\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15185\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15185|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/22/40288\" title=\"figure 1\">",
"      Coronary steal physiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9609?source=related_link\">",
"      Blunt thoracic aortic injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39560?source=related_link\">",
"      Endovascular devices for thoracic aortic repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/7/10361?source=related_link\">",
"      Management and outcome of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37240?source=related_link\">",
"      Thoracic endovascular aneurysm repair",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_45_8922="Insulin regular: Drug information";
var content_f8_45_8922=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin regular: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/37/1621?source=see_link\">",
"    see \"Insulin regular: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/44/36551?source=see_link\">",
"    see \"Insulin regular: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2105104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HumuLIN&reg; R;",
"     </li>",
"     <li>",
"      HumuLIN&reg; R U-500;",
"     </li>",
"     <li>",
"      NovoLIN&reg; R",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2104962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humulin&reg; R;",
"     </li>",
"     <li>",
"      Novolin&reg; ge Toronto",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2104964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Insulin, Short-Acting",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2104988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Diabetes mellitus:",
"     </b>",
"     SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Insulin requirements vary dramatically between patients and therapy requires dosage adjustments with careful medical supervision. Specific formulations may require distinct administration procedures; please see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Type 1:",
"      </i>",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily injections (MDI) guided by blood glucose monitoring or the use of continuous subcutaneous insulin infusions (CSII) is the standard of care for patients with type 1 diabetes. Combinations of insulin formulations are commonly used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Initial dose:",
"     </i>",
"     0.5-1.0 units/kg/day in divided doses. Conservative initial doses of 0.2-0.4 units/kg/day may be recommended to avoid the potential for hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Division of daily insulin requirement:",
"     </i>",
"     Generally, 50% to 75% of the total daily dose (TDD) is given as an intermediate- or long-acting form of insulin (in 1-2 daily injections). The remaining portion of the TDD is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting or short-acting form of insulin. Premixed combinations are available that deliver the rapid- or short-acting component at the same time as the intermediate- or long-acting component. Some patients may benefit from the use of CSII which delivers rapid-acting insulin as a continuous infusion throughout the day and as boluses at mealtimes via an external pump device.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Adjustment of dose:",
"     </i>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain preprandial plasma glucose between 70-130 mg/dL for most patients. Since treatment regimens often consist of multiple formulations, dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient&rsquo;s impaired glycemic control. Treatment and monitoring regimens must be individualized. Also see Additional Information or Pharmacotherapy Pearls.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Usual maintenance range:",
"     </i>",
"     0.5-1.2 units/kg/day in divided doses. Insulin requirements are patient-specific and may vary based on age, body weight, and/or activity factors:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: May require as much as 1.5 units/kg/day during puberty (Silverstein, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Prepuberty: 0.7-1 unit/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Type 2:",
"      </i>",
"     </b>",
"     The goal of therapy is to achieve an Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     &lt;7% as quickly as possible using the safe titration of medications. According to a consensus statement by the ADA and European Association for the Study of Diabetes (EASD), basal insulin therapy (eg, intermediate- or long-acting insulin) should be considered in patients with type 2 diabetes who fail to achieve glycemic goals with lifestyle interventions and metformin &plusmn; a sulfonylurea. Pioglitazone or a GLP-1 agonist may also be considered prior to initiation of basal insulin therapy. In patients who continue to fail to achieve glycemic goals despite the addition of basal insulin, intensification of insulin therapy should be considered; this generally consists of multiple daily injections with a combination of insulin formulations (Nathan, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Initial basal insulin dose:",
"     </i>",
"     0.2 units/kg or 10 units/day (Nathan, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Current guidelines recommend that insulin therapy begin with intermediate- or long-acting insulin given at bedtime or long-acting insulin given in the morning (Nathan, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Adjustment of basal insulin dose:",
"     </i>",
"     Increase dose by 2 units/day every 3 days until fasting glucose levels are consistently within target range (70-130 mg/dL); may increase dose in larger increments (eg, 4 units/day) if fasting glucose levels are &gt;180 mg/dL (Nathan, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <b>",
"      Note:",
"     </b>",
"     If the patient experiences hypoglycemia following adjustment, reduce dose by 4 units/day or 10% of total daily dose, whichever is greater (Nathan, 2009). Additional algorithms, such as the &ldquo;1-1-100&rdquo;, &ldquo;2-4-6-8&rdquo;, &ldquo;3-0-3&rdquo;, and &ldquo;3-2-1&rdquo; algorithms, exist to aid in the titration of basal insulin (Davies, 2005; Gerstein, 2006; Meneghini, 2007; Riddle, 2003); therapy should be individualized and based on patient-specific details.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Intensification of therapy:",
"     </i>",
"     Add a second injection of a short-, rapid-, or intermediate-acting insulin as needed based on blood glucose monitoring; the timing of administration and type of insulin added for intensification of therapy depends on the blood glucose level that is consistently out of the target range (eg, preprandial glucose levels before lunch or dinner, postprandial glucose levels, and/or bedtime glucose levels). Additional injections and subsequent dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient&rsquo;s impaired glycemic control. Intensification of therapy can usually begin with a second injection of ~4 units/day followed by adjustments of ~2 units/day every 3 days until the targeted blood glucose is within range (Nathan, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     In the setting of glucose toxicity (loss of beta-cell sensitivity to glucose concentrations), insulin therapy may be used for short-term management to restore sensitivity of beta-cells; in these cases, the dose may need to be rapidly reduced/withdrawn when sensitivity is re-established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Diabetic ketoacidosis (DKA) (unlabeled use):",
"     </b>",
"     Only I.V. regular insulin should be used for severe DKA; use of SubQ rapid-acting insulin analogs (eg, aspart, lispro) may be appropriate for mild-moderate DKA (Kitabchi, 2009). Treatment should continue until reversal of acid-base derangement/ketonemia. Serum glucose is not a direct indicator of these abnormalities, and may decrease more rapidly than correction of the metabolic abnormalities. Also, refer to institution-specific protocols where appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Adults &lt;20 years (Kitabchi, 2004):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     I.V. infusion: 0.1 units/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Adjustment:",
"     </i>",
"     If serum glucose does not fall by 50 mg/dL in the first hour, check hydration status; if acceptable, double insulin dose hourly until glucose levels fall at rate of 50-75 mg/dL per hour. Once serum glucose reaches 250 mg/dL, decrease dose to 0.05-0.1 units/kg/hour; dextrose-containing I.V. fluids should be administered to maintain serum glucose between 150-250 mg/dL until the acidosis clears. After resolution of DKA, supplement I.V. insulin with SubQ insulin as needed until the patient is able to eat and transition fully to a SubQ insulin regimen. An overlap of ~1-2 hours between discontinuation of I.V. insulin and administration of SubQ insulin is recommended to ensure adequate plasma insulin levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     SubQ, I.M. (",
"     <b>",
"      Note:",
"     </b>",
"     Only use the SubQ and I.M route if I.V. infusion access is unavailable): 0.1-0.3 units/kg SubQ bolus, followed by 0.1 units/kg given every hour SubQ or I.M. or 0.15-0.2 units/kg every 2 hours SubQ; continue until acidosis clears, then decrease to 0.05 units/kg given every hour until SubQ replacement dosing can be initiated (Kitabchi, 2004; Wolfsdorf, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Adults &ge;20 years (Kitabchi, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Bolus:",
"     </i>",
"     0.1 units/kg (optional)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Infusion:",
"     </i>",
"     0.1-0.14 units/kg/hour.",
"     <b>",
"      Note:",
"     </b>",
"     If no I.V. bolus was administered, patients should receive a continuous infusion of 0.14 units/kg/hour; lower doses may not achieve adequate insulin concentrations to suppress hepatic ketone body production.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Adjustment:",
"     </i>",
"     If serum glucose does not fall by at least 10% in the first hour, give an I.V. bolus of 0.14 units/kg and continue previous regimen. In addition, if serum glucose does not fall by 50-70 mg/dL in the first hour, the insulin infusion dose should be increased hourly until a steady glucose decline is achieved Once serum glucose reaches 200 mg/dL, decrease infusion dose to 0.02-0.05 units/kg/hour or switch to SubQ rapid-acting insulin (eg, aspart, lispro) at 0.1 units/kg every 2 hours; dextrose-containing I.V. fluids should be administered to maintain serum glucose between 150-250 mg/dL until the acidosis clears. After resolution of DKA, supplement I.V. insulin with SubQ insulin as needed until the patient is able to eat and transition fully to a SubQ insulin regimen. An overlap of ~1-2 hours between discontinuation of I.V. insulin and administration of SubQ insulin is recommended to ensure adequate plasma insulin levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     SubQ, I.M.: According to the 2009 ADA consensus statement on hyperglycemic crises, a rapid-acting insulin analog (eg, aspart, lispro) given every 1-2 hours via the SubQ route may be appropriate for mild-moderate DKA; however, specific dosing recommendations are not provided (Kitabchi, 2009). If using the I.V. route for severe DKA, consider switching to SubQ rapid-acting insulin once serum glucose reaches 200 mg/dL (Kitabchi, 2009). The following dosing regimen from the 2004 ADA position statement recommends regular insulin (Kitabchi, 2004):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Bolus:",
"     </i>",
"     0.4 units/kg;",
"     <b>",
"      Note:",
"     </b>",
"     Give half of the dose (0.2 units/kg) as an I.V. bolus and half of the dose (0.2 units/kg) as SubQ or I.M.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Intermittent:",
"     </i>",
"     0.1 units/kg given every hour SubQ or I.M.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Adjustment:",
"     </i>",
"     If serum glucose does not fall by 50-70 mg/dL in the first hour, administer 10 units hourly by I.V. bolus until glucose levels fall at a rate of 50-70 mg/dL per hour. Once serum glucose reaches 250 mg/dL, decrease dose to 5-10 units SubQ every 2 hours; dextrose-containing I.V. fluids should be administered to maintain serum glucose between 150-250 mg/dL until the acidosis clears.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Gestational diabetes mellitus (unlabeled use):",
"     </b>",
"     Insulin therapy should be considered when medical nutrition therapy has not achieved GDM glycemic goals (fasting plasma glucose: &lt;95 mg/dL; 1-hour postprandial levels: &lt;130-140 mg/dL; 2-hour postprandial levels: &lt;120 mg/dL); dose and timing of administration should be based on frequent monitoring of plasma glucose levels (ACOG, 2001; ADA, 2004). Human insulin may be preferred (ADA, 2004); however, rapid-acting insulin analogues may also be considered (ACOG, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hyperkalemia, moderate-to-severe (unlabeled use):",
"     </b>",
"     I.V.: 10 units regular insulin mixed with 25 g dextrose (50 mL D",
"     <sub>",
"      50",
"     </sub>",
"     W) given over 15-30 minutes (ACLS, 2010); alternatively, 50 mL D",
"     <sub>",
"      50",
"     </sub>",
"     W over 5 minutes followed by 10 units regular insulin I.V. push over seconds may be administered in the setting of imminent cardiac arrest. In patients with ongoing cardiac arrest (eg, PEA with presumed hyperkalemia), administration of D",
"     <sub>",
"      50",
"     </sub>",
"     W over &lt;5 minutes is routine. Effects on potassium are temporary. As appropriate, consider methods of enhancing potassium removal/excretion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hyperosmolar hyperglycemic state (HHS) (unlabeled use):",
"     </b>",
"     Only regular insulin should be used. Infusion should continue until reversal of mental status changes and hyperosmolality. Serum glucose is not a direct indicator of these abnormalities, and may decrease more rapidly than correction of the metabolic abnormalities. Also, refer to institution-specific protocols where appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Adults &lt;20 years (Kitabchi, 2004):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Infusion:",
"     </i>",
"     0.1 units/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Adjustment:",
"     </i>",
"     If serum glucose does not fall by 50 mg/dL in the first hour, check hydration status; if acceptable, double insulin dose hourly until glucose levels fall at rate of 50-75 mg/dL per hour. Once serum glucose reaches 300 mg/dL, decrease dose to 0.05-0.1 units/kg/hour; dextrose-containing I.V. fluids should be administered to maintain serum glucose between 250-300 mg/dL until hyperosmolality clears and mental status returns to normal. After resolution of HHS, supplement I.V. insulin with SubQ insulin as needed until the patient is able to eat and transition fully to a SubQ insulin regimen. An overlap of ~1-2 hours between discontinuation of I.V. insulin and administration of SubQ insulin is recommended to ensure adequate plasma insulin levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     SubQ, I.M. (",
"     <b>",
"      Note:",
"     </b>",
"     Only use the SubQ and I.M route if I.V. infusion access is unavailable): 0.1-0.3 units/kg SubQ bolus, followed by 0.1 units/kg given every hour SubQ or I.M. or 0.15-0.2 units/kg every 2 hours SubQ; continue until resolution of hyperosmolality, then decrease to 0.05 units/kg given every hour until SubQ replacement dosing can be initiated (Kitabchi, 2004; Wolfsdorf, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Adults &ge;20 years (Kitabchi, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Bolus:",
"     </i>",
"     0.1 units/kg bolus (optional)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Infusion:",
"     </i>",
"     0.1-0.14 units/kg/hour.",
"     <b>",
"      Note:",
"     </b>",
"     If no I.V. bolus was administered, patients should receive a continuous infusion of 0.14 units/kg/hour.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Adjustment:",
"     </i>",
"     If serum glucose does not fall by at least 10% in the first hour, give an I.V. bolus of 0.14 units/kg and continue previous regimen. In addition, if serum glucose does not fall by 50-70 mg/dL in the first hour, the insulin infusion dose should be increased hourly until a steady glucose decline is achieved. Once serum glucose reaches 300 mg/dL, decrease dose to 0.02-0.05 units/kg/hour; dextrose-containing I.V. fluids should be administered to maintain serum glucose between 200-300 mg/dL until the patient is mentally alert. After resolution of HHS, supplement I.V. insulin with SubQ insulin as needed until the patient is able to eat and transition fully to a SubQ insulin regimen. An overlap of ~1-2 hours between discontinuation of I.V. insulin and administration of SubQ insulin is recommended to ensure adequate plasma insulin levels.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2104987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/44/36551?source=see_link\">",
"      see \"Insulin regular: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Diabetes mellitus:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Diabetic ketoacidosis (DKA) (unlabeled use):",
"     </b>",
"     Only I.V. regular insulin should be used for severe DKA; use of SubQ rapid-acting insulin analogs (eg, aspart, lispro) may be appropriate for mild-moderate DKA (Kitabchi, 2009). Treatment should continue until reversal of acid-base derangement/ketonemia. Serum glucose is not a direct indicator of these abnormalities, and may decrease more rapidly than correction of the metabolic abnormalities. Also, refer to institution-specific protocols where appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     I.V.: (Kitabchi, 2004):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Infusion:",
"     </i>",
"     0.1 units/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Adjustment:",
"     </i>",
"     If serum glucose does not fall by 50 mg/dL in the first hour, check hydration status; if acceptable, double insulin dose hourly until glucose levels fall at rate of 50-75 mg/dL per hour. Once serum glucose reaches 250 mg/dL, decrease dose to 0.05-0.1 units/kg/hour; dextrose-containing I.V. fluids should be administered to maintain serum glucose between 150-250 mg/dL until the acidosis clears. After resolution of DKA, supplement I.V. insulin with SubQ insulin as needed until the patient is able to eat and transition fully to a SubQ insulin regimen. An overlap of ~1-2 hours between discontinuation of I.V. insulin and administration of SubQ insulin is recommended to ensure adequate plasma insulin levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     SubQ, I.M. (",
"     <b>",
"      Note:",
"     </b>",
"     Only use the SubQ and I.M route if I.V. infusion access is unavailable): 0.1-0.3 units/kg SubQ bolus, followed by 0.1 units/kg given every hour SubQ or I.M. or 0.15-0.2 units/kg every 2 hours SubQ; continue until acidosis clears, then decrease to 0.05 units/kg given every hour until SubQ replacement dosing can be initiated (Kitabchi, 2004; Wolfsdorf, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hyperkalemia, moderate-to-severe (unlabeled use):",
"     </b>",
"     I.V.: 0.1 units/kg regular insulin with dextrose 400 mg/kg infused over 15-30 minutes; ratio of ~1 unit of insulin to every 4 g of dextrose (Hegenbarth, 2008).",
"     <b>",
"      Note:",
"     </b>",
"     Dextrose monotherapy may be sufficient to correct hyperkalemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hyperosmolar hyperglycemic state (HHS) (unlabeled use):",
"     </b>",
"     Only regular insulin should be used. Infusion should continue until reversal of mental status changes and hyperosmolality. Serum glucose is not a direct indicator of these abnormalities, and may decrease more rapidly than correction of the metabolic abnormalities. Also, refer to institution-specific protocols where appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     I.V. (Kitabchi, 2004):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Infusion:",
"     </i>",
"     0.1 units/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Adjustment:",
"     </i>",
"     If serum glucose does not fall by 50 mg/dL in the first hour, check hydration status; if acceptable, double insulin dose hourly until glucose levels fall at rate of 50-75 mg/dL per hour. Once serum glucose reaches 300 mg/dL, decrease dose to 0.05-0.1 units/kg/hour; dextrose-containing I.V. fluids should be administered to maintain serum glucose between 250-300 mg/dL until hyperosmolality clears and mental status returns to normal. After resolution of HHS, supplement I.V. insulin with SubQ insulin as needed until the patient is able to eat and transition fully to a SubQ insulin regimen. An overlap of ~1-2 hours between discontinuation of I.V. insulin and administration of SubQ insulin is recommended to ensure adequate plasma insulin levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     SubQ, I.M. (",
"     <b>",
"      Note:",
"     </b>",
"     Only use the SubQ and I.M route if I.V. infusion access is unavailable): 0.1-0.3 units/kg SubQ bolus, followed by 0.1 units/kg given every hour SubQ or I.M. or 0.15-0.2 units/kg every 2 hours SubQ; continue until resolution of hyperosmolality, then decrease to 0.05 units/kg given every hour until SubQ replacement dosing can be initiated (Kitabchi, 2004; Wolfsdorf, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2104989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2104990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Insulin requirements are reduced due to changes in insulin clearance or metabolism. Close monitoring of blood glucose and adjustment of therapy is required in renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer at 75% of normal dose and monitor glucose closely",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer at 25% to 50% of normal dose and monitor glucose closely",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Because of a large molecular weight (6000 daltons), insulin is not significantly removed by hemodialysis; supplemental dose is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Because of a large molecular weight (6000 daltons), insulin is not significantly removed by peritoneal dialysis; supplemental dose is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy: Administer 75% of normal dose and monitor glucose closely; supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8092960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin requirements may be reduced. Close monitoring of blood glucose and adjustment of therapy is required in hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HumuLIN&reg; R: 100 units/mL (3 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NovoLIN&reg; R: 100 units/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HumuLIN&reg; R U-500: 500 units/mL (20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2104963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2104992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SubQ administration: Do not use if solution is viscous or cloudy; use only if clear and colorless. Regular insulin should be administered within 30-60 minutes before a meal. Cold injections should be avoided. SubQ administration is usually made into the thighs, arms, buttocks, or abdomen; rotate injection sites. When mixing regular insulin with other preparations of insulin, regular insulin should be drawn into syringe first. Regular insulin is not recommended for use in external SubQ insulin infusion pump.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M. administration: Do not use if solution is viscous or cloudy; use only if clear and colorless. May be administered I.M. in selected clinical situations; close monitoring of blood glucose and serum potassium as well as medical supervision is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     I.V. administration: Do not use if solution is viscous or cloudy; use only if clear and colorless. May be administered I.V. with close monitoring of blood glucose and serum potassium; appropriate medical supervision is required. If possible, avoid I.V. bolus administration in pediatric patients with DKA; may increase risk of cerebral edema.",
"     <b>",
"      Do not administer mixtures of insulin formulations intravenously.",
"     </b>",
"     I.V. administration of U-500 regular insulin is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. infusions: To minimize adsorption to I.V. solution bag (",
"     <b>",
"      Note:",
"     </b>",
"     Refer to institution-specific protocols where appropriate):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      If new tubing is",
"     </i>",
"     <b>",
"      <i>",
"       not",
"      </i>",
"     </b>",
"     <i>",
"      needed:",
"     </i>",
"     Wait a minimum of 30 minutes between the preparation of the solution and the initiation of the infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      If new tubing is needed:",
"     </i>",
"     After receiving the insulin drip solution, the administration set should be attached to the I.V. container and the entire line should be flushed with a priming infusion of 20-50 mL of the insulin solution (Goldberg, 2006; Hirsch, 2006). Wait 30 minutes, then flush the line again with the insulin solution prior to initiating the infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If insulin is required prior to the availability of the insulin drip, regular insulin should be administered by I.V. push injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Because of adsorption, the actual amount of insulin being administered via I.V. infusion could be substantially less than the apparent amount. Therefore, adjustment of the I.V. infusion rate should be based on effect and not solely on the apparent insulin dose. The apparent dose may be used as a starting point for determining the subsequent SubQ dosing regimen (Moghissi, 2009); however, the transition to SubQ administration requires continuous medical supervision, frequent monitoring of blood glucose, and careful adjustment of therapy. In addition, SubQ insulin should be given 1-4 hours prior to the discontinuation of I.V. insulin to prevent hyperglycemia (Moghissi, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14472660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     100 units in 100 mL (concentration: 1 unit/mL) of NS",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     0.1 unit/mL, 0.5 unit/mL,",
"     <b>",
"      or",
"     </b>",
"     1 unit/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2104980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W and NS.",
"     <b>",
"      Note:",
"     </b>",
"     A universal sterile diluent, Sterile Diluent for Humalog&reg;, Humulin&reg; N, Humulin&reg; R, Humulin&reg; 70/30, and Humulin&reg; R U-500, is available from the manufacturer for SubQ administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alcohol (ethyl), amiodarone, ampicillin, ampicillin/sulbactam, aztreonam, caspofungin, cefazolin, cefepime, cefotetan, ceftazidime, dobutamine, doripenem, esmolol, famotidine, gentamicin, heparin, heparin with hydrocortisone sodium succinate, imipenem/cilastatin, indomethacin, magnesium sulfate, meperidine, meropenem, midazolam, milrinone, morphine, nitroglycerin, nitroprusside, oxytocin, pancuronium, pentobarbital, potassium chloride, propofol, sodium bicarbonate, tacrolimus, terbutaline, ticarcillin/clavulanate, tobramycin, vancomycin, vasopressin, vecuronium, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Dopamine, drotrecogin alfa, micafungin, nafcillin, nesiritide, ranitidine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Digoxin, diltiazem, doxapram, labetalol, levofloxacin, norepinephrine, pantoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Insulin NPH, metoclopramide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Insulin aspart, insulin detemir, insulin glargine, insulin glulisine, insulin lispro, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Lidocaine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2105108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 1 diabetes mellitus (insulin dependent, IDDM) and type 2 diabetes mellitus (noninsulin dependent, NIDDM) to improve glycemic control",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F2105109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hyperkalemia; gestational diabetes mellitus (GDM), diabetic ketoacidosis (DKA); hyperosmolar hyperglycemic state (HHS); adjunct of parenteral nutrition",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2104961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       HumuLIN&reg; R may be confused with HumaLOG&reg;, Humira&reg;, HumuLIN&reg; 70/30, HumuLIN&reg; N, NovoLIN&reg; 70/30, NovoLIN&reg; R, NovoLOG&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       NovoLIN&reg; R may be confused with HumuLIN&reg; R, NovoLIN&reg; 70/30, NovoLIN&reg; N, NovoLOG&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Concentrated solutions (eg, U-500) should not be available in patient care areas. U-500 regular insulin should be stored, dispensed, and administered separately from U-100 regular insulin. For patients who receive U-500 insulin in the hospital setting, highlighting the strength prominently on the patient&rsquo;s medical chart and medication record may help to reduce dispensing errors.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2104970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Primarily symptoms of hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy or hypertrophy of SubQ fat tissue; edema, itching, pain or warmth at injection site; stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, local and/or systemic hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2104968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to regular insulin or any component of the formulation; during episodes of hypoglycemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2105113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from increased work or exercise without eating; use of long-acting insulin preparations (eg, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage, or even death. Insulin requirements may be altered during illness, emotional disturbances, or other stressors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Insulin (especially I.V. insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium frequently with I.V. use and supplement potassium when necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of sliding scale insulin in this population due to increased risk of hypoglycemia without benefits in management of hyperglycemia regardless of care setting (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product variation: Human insulin differs from animal-source insulin. Any change of insulin should be made cautiously; changing manufacturers, type, and/or method of manufacture may result in the need for a change of dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; U-500 regular insulin: U-500 regular insulin is a concentrated insulin formulation which contains 500 units of insulin per mL; for SubQ administration only using a U-100 insulin syringe or tuberculin syringe;",
"     <b>",
"      not for I.V. administration",
"     </b>",
"     . To avoid dosing errors when using a U-100 insulin syringe, the prescribed dose should be written in actual insulin units and as unit markings on the U-100 insulin syringe (eg, 50 units [10 units on a U-100 insulin syringe]). To avoid dosing errors when using a tuberculin syringe, the prescribed dose should be written in actual insulin units and as a volume (eg, 50 units [0.1 mL]). Mixing U-500 regular insulin with other insulin formulations is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Diabetes mellitus: The general objective of exogenous insulin therapy is to approximate the physiologic pattern of insulin secretion which is characterized by two distinct phases. Phase 1 insulin secretion suppresses hepatic glucose production and phase 2 insulin secretion occurs in response to carbohydrate ingestion; therefore, exogenous insulin therapy may consist of basal insulin (eg, intermediate- or long-acting insulin via continuous subcutaneous insulin infusion [CSII]) and/or preprandial insulin (eg, short- or rapid-acting insulin) (see Related Information: Insulin Products). Patients with type 1 diabetes do not produce endogenous insulin; therefore, these patients require both basal and preprandial insulin administration. Patients with type 2 diabetes retain some beta-cell function in the early stages of their disease; however, as the disease progresses, phase 1 insulin secretion may become completely impaired and phase 2 insulin secretion becomes delayed and/or inadequate in response to meals. Therefore, patients with type 2 diabetes may be treated with oral antidiabetic agents, basal insulin, and/or preprandial insulin depending on the stage of disease and current glycemic control. Since treatment regimens often consist of multiple agents, dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient&rsquo;s impaired glycemic control. Treatment and monitoring regimens must be individualized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.M. administration: Regular insulin may be administered I.M. in selected clinical situations to control hyperglycemia (eg, DKA); close monitoring of blood glucose and serum potassium as well as medical supervision is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.V. administration: Regular insulin may be administered I.V. in selected clinical situations (eg, DKA, hyperkalemia); close monitoring of blood glucose and serum potassium as well as medical supervision is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2104975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2104974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2104978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Use caution with ethanol; may increase risk of hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Use caution with alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle; may increase risk of hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F14079518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2105111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Minimal amounts of endogenous insulin cross the placenta. Exogenous insulin bound to anti-insulin antibodies has been detected in cord blood. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is &gt;1% above the normal range. Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28-32 weeks of gestation. Following delivery, insulin requirements decrease rapidly. Diabetes can also be associated with adverse effects in the mother. Poorly treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the fetus and the mother. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2104966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2104967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Endogenous insulin can be found in breast milk. Plasma glucose concentrations in the mother affect glucose concentrations in breast milk. The gastrointestinal tract destroys insulin when administered orally; therefore, insulin is not expected to be absorbed intact by the breast-feeding infant. All types of insulin are safe for use while breast-feeding. Due to increased calorie expenditure, women with diabetes may require less insulin while nursing.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2104991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (HumuLIN R Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (10 mL): $21.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (HumuLIN R U-500 (CONCENTRATED) Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 units/mL (20 mL): $912.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (NovoLIN R Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (10 mL): $90.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (NovoLIN R ReliOn Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (10 mL): $90.95",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2104996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diabetes mellitus: Plasma glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DKA/HHS: Serum electrolytes, glucose, BUN, creatinine, osmolality, venous pH (repeat arterial blood gases are generally unnecessary), anion gap, urine output, urinalysis, mental status",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyperkalemia: Serum potassium and glucose must be closely monitored to avoid hypokalemia, rebound hyperkalemia, and hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2105121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Therapeutic, serum insulin (fasting): 5-20 &mu;IU/mL (SI: 35-145 pmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose, fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elderly: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommendations for glycemic control in adults with diabetes mellitus:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak postprandial capillary plasma glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actraphane (AT, BE, BG, CH, CZ, DE, DK, ES, FI, FR, GB, GR, HN, IE, IT, NL, NO, PT, RU, SE, TR);",
"     </li>",
"     <li>",
"      Actrapid (AT, BE, BG, CH, CZ, DE, DK, ES, FI, FR, GB, GR, HN, IE, IL, IT, NL, NO, PT, RU, SE, TR);",
"     </li>",
"     <li>",
"      Actrapid HM (AE, BF, BH, BJ, CI, CY, DE, EG, ET, GH, GM, GN, HK, IL, IQ, IR, IT, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, OM, PH, QA, SA, SC, SD, SL, SN, SY, TH, TN, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Actrapid Human (ID, JP);",
"     </li>",
"     <li>",
"      Berlinsulin Actrapid Normal U-40 (DE);",
"     </li>",
"     <li>",
"      Berlinsulin H Basal U-40 (DE);",
"     </li>",
"     <li>",
"      Biohulin (KP);",
"     </li>",
"     <li>",
"      Gensulin R (TH);",
"     </li>",
"     <li>",
"      Human Actrapid (IE, IN);",
"     </li>",
"     <li>",
"      Human Nordisulin (IN);",
"     </li>",
"     <li>",
"      Huminsulin \"Lilly\" Normal (AT);",
"     </li>",
"     <li>",
"      Huminsulin Normal (CH, DE);",
"     </li>",
"     <li>",
"      Humulin (Regular) (GR);",
"     </li>",
"     <li>",
"      Humulin R (AE, AU, BB, BF, BG, BH, BJ, BM, BS, BZ, CI, CL, CO, CR, CY, CZ, DO, EE, EG, ET, GH, GM, GN, GT, GY, HK, HN, IL, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NI, NL, OM, PA, PE, PH, PK, PY, QA, SA, SC, SD, SL, SN, SR, SV, SY, TH, TN, TT, TZ, UG, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Humulin Regular (DK, FI, NO, PT, SE, TW);",
"     </li>",
"     <li>",
"      Humulina Regular (ES);",
"     </li>",
"     <li>",
"      Insulin \"Novo Nordisk\" Actrapid HM (AT);",
"     </li>",
"     <li>",
"      Insulin \"Novo Nordisk\" Velosulin HM (AT);",
"     </li>",
"     <li>",
"      Insulin Actrapid HM (BG);",
"     </li>",
"     <li>",
"      Insulin Hoechst-Rapid U-100 (CH);",
"     </li>",
"     <li>",
"      Insulin Human Actrapid (GB);",
"     </li>",
"     <li>",
"      Insulina (ES);",
"     </li>",
"     <li>",
"      Insulina Actrapid HM (ES);",
"     </li>",
"     <li>",
"      Insulina Humulin R (AR);",
"     </li>",
"     <li>",
"      Insulina Velosulin HM (ES);",
"     </li>",
"     <li>",
"      Insuline (NL);",
"     </li>",
"     <li>",
"      Insuline Actrapid (NL);",
"     </li>",
"     <li>",
"      Insuline Humuline Regular (NL);",
"     </li>",
"     <li>",
"      Insuline Velosulin Humaan (NL);",
"     </li>",
"     <li>",
"      Insuman (AT, BE, BG, BR, CH, CN, CZ, DE, DK, ES, FI, FR, GB, GR, HN, IE, IT, NL, NO, PT, RU, SE, TR);",
"     </li>",
"     <li>",
"      Insuman Basal (DE);",
"     </li>",
"     <li>",
"      Insuman Infusat (DE);",
"     </li>",
"     <li>",
"      Insuman R (EC);",
"     </li>",
"     <li>",
"      Insuman Rapid (DE);",
"     </li>",
"     <li>",
"      Novolet R (KP);",
"     </li>",
"     <li>",
"      Novolin R (CL, EC, KP, PE);",
"     </li>",
"     <li>",
"      Orgasulin Rapid (FR);",
"     </li>",
"     <li>",
"      Ransulin-R (PH);",
"     </li>",
"     <li>",
"      Scilin R (HK, PH);",
"     </li>",
"     <li>",
"      Velosulin (AT, BE, BG, CH, CZ, DE, DK, ES, FI, FR, GB, GR, HN, IE, IT, NL, NO, PT, RU, SE, TR);",
"     </li>",
"     <li>",
"      Velosulin HM (AT);",
"     </li>",
"     <li>",
"      Velosuline Humaine (FR);",
"     </li>",
"     <li>",
"      Wosulin-R (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2104981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes; also directly inhibits the hydrolysis of triglycerides. In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Saccharomyces cerevisiae",
"     </i>",
"     . Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2104982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Rate of absorption, onset, and duration of activity may be affected by site of injection, exercise, presence of lipodystrophy, local blood supply, and/or temperature.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: SubQ: 0.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: SubQ: 2.5-5 hours",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Duration: SubQ:",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;\">",
"     U-100: 4-12 hours (may increase with dose)",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;\">",
"     U-500: Up to 24 hours",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.26-0.36 L/kg",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Bioavailability: SubQ: 55% to 77%",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Half-life elimination: I.V.: ~0.5-1 hour (dose-dependent); SubQ: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Time to peak, plasma: SubQ: 0.8-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists Committee on Practice Bulletins, &ldquo;ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 30, September 2001 (Replaces Technical Bulletin Number 200, December 1994). Gestational Diabetes,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2001, 98(3):525-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/11547793/pubmed\" id=\"11547793\" target=\"_blank\">",
"        11547793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Gestational Diabetes Mellitus,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(Suppl 1):88-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/14693936/pubmed\" id=\"14693936\" target=\"_blank\">",
"        14693936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity, &ldquo;Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(2):596-601.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/14747245/pubmed\" id=\"14747245\" target=\"_blank\">",
"        14747245",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Type 2 Diabetes in Children and Adolescents,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2000, 23(3):381-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/10868870/pubmed\" id=\"10868870\" target=\"_blank\">",
"        10868870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown G and Dodek P, &ldquo;Intravenous Insulin Nomogram Improves Blood Glucose Control in the Critically Ill,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2001, 29(9):1714-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/11546970/pubmed\" id=\"11546970\" target=\"_blank\">",
"        11546970",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brunkhorst FM, Engel C, Bloos F, et al, &ldquo;Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(2):125-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/18184958/pubmed\" id=\"18184958\" target=\"_blank\">",
"        18184958",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 2008, 32(suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dailey G, &ldquo;New Strategies for Basal Insulin Treatment in Type 2 Diabetes Mellitus,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2004, 26(6):889-901.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies M, Storms F, Shutler S, et al, &ldquo;Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2005, 28(6):1282-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/15920040/pubmed\" id=\"15920040\" target=\"_blank\">",
"        15920040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Deedwania P, Kosiborod M, Barrett E, et al, &ldquo;Hyperglycemia and Acute Coronary Syndrome: A Scientific Statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117(12):1610-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/18299505/pubmed\" id=\"18299505\" target=\"_blank\">",
"        18299505",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo; [published correction appears in",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(4):1394-6],",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(1):296-327.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/18158437/pubmed\" id=\"18158437\" target=\"_blank\">",
"        18158437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerstein HC, Yale JF, Harrist SB, et al, &ldquo;A Randomized Trial of Adding Insulin Glargine Vs. Avoidance of Insulin in People with Type 2 Diabetes on Either No Oral Glucose-Lowering Agents or Submaximal Doses of Metformin and/or Sulphonylureas: The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study,&rdquo;",
"      <i>",
"       Diabet Med",
"      </i>",
"      , 2006, 23(7):736-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/16842477/pubmed\" id=\"16842477\" target=\"_blank\">",
"        16842477",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldberg PA, Kedves A, Walter K, et al, &ldquo;'Waste Not, Want Not': Determining Optimal Priming Volume for Intravenous Insulin Infusions,&rdquo;",
"      <i>",
"       Diabetes Technol Ther",
"      </i>",
"      , 2006, 8(5):598-601.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/17037974/pubmed\" id=\"17037974\" target=\"_blank\">",
"        17037974",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2011, 17(Suppl 2):1-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/21474420/pubmed\" id=\"21474420\" target=\"_blank\">",
"        21474420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo;",
"      <i>",
"       Pediatrics,",
"      </i>",
"      2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hirsch IB, &ldquo;Evidence-Based Priming,&rdquo;",
"      <i>",
"       Diabetes Technol Ther",
"      </i>",
"      , 2006, 8(5):521-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/17037966/pubmed\" id=\"17037966\" target=\"_blank\">",
"        17037966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holman RR and Turner RC, &ldquo;Insulin Therapy in Type II Diabetes,&rdquo;",
"      <i>",
"       Diabetes Res Clin Pract",
"      </i>",
"      , 1995, (28 Suppl):179-84.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hopkins DF, Cotton SJ, and Williams G, &ldquo;Effective Treatment of Insulin-Induced Edema Using Ephedrine,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 1993, 16(7):1026-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/8359096/pubmed\" id=\"8359096\" target=\"_blank\">",
"        8359096",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011.  Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobi J, Bircher N, Krinsley J, et al, &ldquo;Guidelines for the Use of an Insulin Infusion for the Management of Hyperglycemia in Critically Ill Patients,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2012, 40(12):3251-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/23164767/pubmed\" id=\"23164767\" target=\"_blank\">",
"        23164767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joint Commission on Accreditation of Healthcare Organizations, &ldquo;2005 National Patient Safety Goals.&rdquo; Available at file://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/05_npsgs.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kitabchi AE, Umpierrez GE, Miles JM, et al, &ldquo;Hyperglycemic Crises in Adult Patients With Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(7):1335-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/19564476/pubmed\" id=\"19564476\" target=\"_blank\">",
"        19564476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kitabchi AE, Umpierrez GE, Murphy MB, et al, \"Hyperglycemic Crises in Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(Suppl 1): 94-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/14693938/pubmed\" id=\"14693938\" target=\"_blank\">",
"        14693938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kushner FG, Hand M, Smith SC, et al, &ldquo;2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(23):2205-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/19942100/pubmed\" id=\"19942100\" target=\"_blank\">",
"        19942100",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lazar HL, Philippides G, Fitzgerald C, et al, &ldquo;Glucose-Insulin-Potassium Solutions Enhance Recovery After Urgent Coronary Artery Bypass Grafting,&rdquo;",
"      <i>",
"       J Thorac Cardiovasc Surg",
"      </i>",
"      , 1997, 113(2):354-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/9040630/pubmed\" id=\"9040630\" target=\"_blank\">",
"        9040630",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malhotra A, &ldquo;Intensive Insulin in Intensive Care,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(5):516-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/16452564/pubmed\" id=\"16452564\" target=\"_blank\">",
"        16452564",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malmberg K, &ldquo;Prospective Randomised Study of Intensive Insulin Treatment on Long Term Survival After Acute Myocardial Infarction in Patients With Diabetes Mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1997, 314(7093):1512-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/9169397/pubmed\" id=\"9169397\" target=\"_blank\">",
"        9169397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meneghini L, Koenen C, Rojas P, et al, &ldquo;Efficacy and Safety of Insulin Detemir in a Large Cohort of Patients With Type 2 Diabetes Using a Simplified Self-Adjusted Dosing Guideline -- Results of the Predictive 303 Study,&rdquo; Presented at: 67th Scientific Sessions of the American Diabetes Association; June 22-25, 2007; Chicago, Ill.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moghissi ES, Korytkowski MT, DiNardo M, et al, &ldquo;American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(4):353-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/19454396/pubmed\" id=\"19454396\" target=\"_blank\">",
"        19454396",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morley JE and Perry HM 3d, &ldquo;The Management of Diabetes Mellitus in Older Individuals,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1991, 41(4):548-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/1711959/pubmed\" id=\"1711959\" target=\"_blank\">",
"        1711959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mueller-Schoop J, &ldquo;Accidental Intravenous Self-Injection With Insulin Pen,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1993, 341(8849):894.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nathan DM, Buse, JB, Davidson MB, et al, &ldquo;Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(1):193-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/18945920/pubmed\" id=\"18945920\" target=\"_blank\">",
"        18945920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nathan DM, &ldquo;Insulin Treatment in the Elderly Diabetic Patient,&rdquo;",
"      <i>",
"       Clin Geriatr Med",
"      </i>",
"      , 1990, 6(4):923-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/2224755/pubmed\" id=\"2224755\" target=\"_blank\">",
"        2224755",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al, &ldquo;Intensive Versus Conventional Glucose Control in Critically Ill Patients,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(13):1283-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/19318384 /pubmed\" id=\"19318384 \" target=\"_blank\">",
"        19318384",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oiknine R, Bernbaum M, and Mooradian AD, &ldquo;A Critical Appraisal of the Role of Insulin Analogues in the Management of Diabetes Mellitus,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2005, 65(3):325-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/15669878/pubmed\" id=\"15669878\" target=\"_blank\">",
"        15669878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Proceedings of the American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control Consensus Conference, Washington, DC, USA, December 2003,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2004, (10 Suppl 2):3-108.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Chou R, et al, \"Use of Intensive Insulin Therapy for the Management of Glycemic Control in Hospitalized Patients: A Clinical Practice Guideline From the American College of Physicians,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2011, 154(4):260-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/21320941/pubmed\" id=\"21320941\" target=\"_blank\">",
"        21320941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riddle MC, Rosenstock J, Gerich J, et al, &ldquo;The Treat-to-Target Trial: Randomized Addition of Glargine or Human NPH Insulin to Oral Therapy of Type 2 Diabetic Patients,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2003, 26(11):3080-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/14578243/pubmed\" id=\"14578243\" target=\"_blank\">",
"        14578243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverstein J, Klingensmith G, Copeland K, et al, &ldquo;Care of Children and Adolescents With Type 1 Diabetes: A Statement of the American Diabetes Association,&rdquo;",
"      <i>",
"       Diabetes Care,",
"      </i>",
"      2005, 28(1):186-212.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/15616254/pubmed\" id=\"15616254\" target=\"_blank\">",
"        15616254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simeon PS, Geffner ME, Levin SR, et al, &ldquo;Continuous Insulin Infusions in Neonates: Pharmacologic Availability of Insulin in Intravenous Solutions,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 124(5 Pt 1):818-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/8176576/pubmed\" id=\"8176576\" target=\"_blank\">",
"        8176576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van den Berghe G, Wilmer A, Hermans G, et al, &ldquo;Intensive Insulin Therapy in the Medical ICU,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(5):449-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/16452557/pubmed\" id=\"16452557\" target=\"_blank\">",
"        16452557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van den Berghe G, Wouters P, Weekers F, et al, &ldquo;Intensive Insulin Therapy in the Critically Ill Patients,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(19):1359-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/11794168/pubmed\" id=\"11794168\" target=\"_blank\">",
"        11794168",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vanden Hoek TL, Morrison LJ, Shuster M, et al, &ldquo;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):829-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/20956228/pubmed\" id=\"20956228\" target=\"_blank\">",
"        20956228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiener RS, Wiener DC, and Larson RJ, &ldquo;Benefits and Risks of Tight Glucose Control in Critically Ill Adults: A Meta-Analysis,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2008, 300(8):933-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/18728267/pubmed\" id=\"18728267\" target=\"_blank\">",
"        18728267",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wolfsdorf J, Craig ME, Daneman D, et al, &ldquo;Diabetic Ketoacidosis,&rdquo;",
"      <i>",
"       Pediatr Diabetes",
"      </i>",
"      , 2007, 8(1):28-43. Available at file://www.ispad.org/FileCenter/10-Wolfsdorf_Ped_Diab_2007,8.28-43.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/45/8922/abstract-text/17341289/pubmed\" id=\"17341289\" target=\"_blank\">",
"        17341289",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9030 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_45_8922=[""].join("\n");
var outline_f8_45_8922=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2105104\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104962\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104964\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104988\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104987\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104989\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104990\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8092960\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104923\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104963\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104992\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472660\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472661\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104980\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2105108\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2105109\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104961\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104970\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104968\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2105113\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104975\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104974\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104978\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079518\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2105111\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104966\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104967\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104991\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422171\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104996\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2105121\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038885\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104981\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104982\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9030\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9030|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/37/1621?source=related_link\">",
"      Insulin regular: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/44/36551?source=related_link\">",
"      Insulin regular: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_45_8923="NYHA alter pulm thromboend";
var content_f8_45_8923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Improvement in NYHA functional class after pulmonary thromboendarterectomy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        NYHA class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preoperative",
"       </td>",
"       <td class=\"subtitle1\">",
"        Postoperative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        117",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Marked improvement in New York Heart Association (NYHA) functional class after pulmonary thromboendartectomy for chronic thromboembolic pulmonary hypertension in 117 of the first 150 patients evaluated at one year following surgery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_45_8923=[""].join("\n");
var outline_f8_45_8923=null;
var title_f8_45_8924="Binet staging system CLL";
var content_f8_45_8924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80421%7EHEME%2F56284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80421%7EHEME%2F56284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Binet Staging System For Chronic Lymphocytic Leukemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle1\">",
"       Description",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Two or less lymphoid bearing areas enlarged*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       B",
"      </td>",
"      <td>",
"       Three or more lymphoid bearing areas enlarged*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       C",
"      </td>",
"      <td>",
"       Presence of anemia (Hgb &lt;10.0 g/dL) or thrombocytopenia (platelet count &lt;100,000/microL)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Five lymphoid bearing areas are possible: cervical, axillary, inguino-femoral, spleen, and liver.",
"    </div>",
"    <div class=\"reference\">",
"     Revised from Binet, JL, Auquier, A, Dighiero, G, et al. Cancer 1981; 48:198.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified Rai clinical staging system for chronic lymphocytic leukemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk",
"       </td>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Lymphocytosis in blood or bone marrow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Intermediate",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        Lymphocytosis + enlarged lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        Lymphocytosis + enlarged liver or spleen with or",
"without lymphadenopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        High",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        Lymphocytosis + anemia (Hgb &lt;11 g/dL)",
"with&nbsp;or without enlarged liver, spleen, or lymph lnodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Lymphocytosis + thrombocytopenia (platelet count",
"&lt;100,000/&micro;L) with or without anemia or enlarged liver,",
"spleen, or lymph nodes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_45_8924=[""].join("\n");
var outline_f8_45_8924=null;
var title_f8_45_8925="Common drugs for external otitis";
var content_f8_45_8925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antibiotic, antiseptic, glucocorticoid, and acidifying solutions for external otitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Product name (preparation)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antibiotic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antiseptic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Glucocorticoid",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acid",
"       </td>",
"       <td class=\"subtitle1\">",
"        pH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Antibiotic solutions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cortisporin Otic Suspension (ear)",
"       </td>",
"       <td>",
"        Polymyxin B; Neomycin",
"       </td>",
"       <td>",
"        Alcohol",
"       </td>",
"       <td>",
"        Hydrocortisone",
"       </td>",
"       <td>",
"        Sulfuric",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cortisporin Otic Solution (ear)",
"       </td>",
"       <td>",
"        Polymyxin B; Neomycin",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Hydrocortisone",
"       </td>",
"       <td>",
"        Hydrochloric",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coly-Mycin S Otic (ear)",
"       </td>",
"       <td>",
"        Colistin; Neomycin",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Hydrocortisone",
"       </td>",
"       <td>",
"        Acetic",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cipro HC Otic (ear)",
"       </td>",
"       <td>",
"        Ciprofloxacin",
"       </td>",
"       <td>",
"        Alcohol",
"       </td>",
"       <td>",
"        Hydrocortisone",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        4.5-5.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Floxin Otic (ear)",
"       </td>",
"       <td>",
"        Ofloxacin",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        6.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Antiseptic solutions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cresylate (ear)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        m-Cresyl acetate; alcohol",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Acetic",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gentian violet (skin)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Gentian violet",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        6.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Glucocorticoid solutions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Decadron ophthalmic solution (eye)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Dexamethasone",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        7.4-7.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Glucocorticoid and acidifying solutions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        VoSol HC (ear)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Alcohol",
"       </td>",
"       <td>",
"        Hydrocortisone",
"       </td>",
"       <td>",
"        Acetic",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Acidifying solutions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        VoSol (ear)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Alcohol",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Acetic",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Octic Domeboro (ear)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Boric",
"       </td>",
"       <td>",
"        4.5-6.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_45_8925=[""].join("\n");
var outline_f8_45_8925=null;
var title_f8_45_8926="Acute retinal necrosis";
var content_f8_45_8926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute retinal necrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 280px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Funduscopic photograph of a patient with acute retinal necrosis showing a characteristic patchy white yellow area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Tolentino, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_45_8926=[""].join("\n");
var outline_f8_45_8926=null;
var title_f8_45_8927="Osteonecrosis of the jaw";
var content_f8_45_8927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F55727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F55727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteonecrosis of the jaw: radiographic appearance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 291px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEjAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UoqWaRHjgVIgjIm12BJ3ncTuPpwQPwqKgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACpIZZIJVkhkeORTlXQ4I+hFR0UAPmkkmlaSZ2kkY5ZmOST7mnpczx27wRzyrA5y8YchW+o6GoaKACiiigAooooAUUtIKWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAHzTvLHAj42wpsTAxxuLc+vLGoqKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKlt4XnkCRqST6UARU9I3c/IpP0rq9O8NLtVp8luuK3rfTLaDG2Mce1AHA22l3VwfkiP41ci8PXjNhlwMZzXfJHHExKKAMU7cMdsAUAcV/wis3eSpI/Ckhfa8hHNdfvwOe54pTJh+vvQBxFx4YuEXMTbue9U5tAvo13eXn6V6EW4x9KXIJwcdKAPLpLK4jJDxOMe1QEEHBGDXqrRxuBlFOfas3UNDtbtc7QrEdRQB53RXRXfhi4jP7khx71jXVlPasVmjK479qAK4paQUZoAWikzS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiilFACUVftNKu7nBSMhT3NdPp3hmKIK9ydzelAHPaTo0986kgrGe9dnpul29ioCqC3qatqsUCKkYAAGKgDlic9KALHmgfXNNEuWPrUK/MPfNPVfmHvQBLuyuaACUPuaFT5frUpA2cd6AISDgHsDimnIdhVgj5PxpoXpQBWLMM5+lO8w7jjtUjx9eOppm3HNACmXbgntQsw2jJqGTJwe1MI2/nQBcMgMpOe1NlghuY8SorA1VOQRz14q1yidaAOa1bwyAhkszz121ys8TwSFJVKsOxr1ISjABrO1XSINQjZsBZOxFAHnVKKualp81hMUlU47GqYoAWikzS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUANooooAKKKKACiiigAooooAKKKKACiiigAoorY0PSWvJBJKCIQevrQBX03S7i+cBFITuxrrtO8P2tqu6T53960LdY4Y/LiUKAO1KJeoPPFAD1ZIhtVQAPQUkk+Vx7VCrhsk9xSOAcjsRxQA0MWGaM4NNUEKAakVcoc+lACx5PNWUHyqD1FRRoQuPSrKj5QTQA7HyqPTrR93H0pSMKx71FNKN2BQBIMEAUgwOT0zXTfCjRrPxN4/0zSdTV2tLjzd4Rtp+WJ2GD9VFUPF+nQ6X4n1mwtAwt7W9mgjDHJ2rIQMnvwKAMhz8qZpHUdfahz93PbinLzj2oArSLtxUTDIGeBVpgWXNBQFBkUAVNuAM/WhmYNirEiYwaZInzgjvQBEThx71ZibBx2qAL8+D2NOXPm4FAC6lZxX8BSRRkjg1wOraVNYSkMpMfZq9EUkFc9AaS5gjuYmSRQQfWgDyqnVua7ob2bb4AWjPP0rDPBwaACikzRmgBaKTNGaAFopM0ZoAWikzRmgBaKTNGaAFopM0ZoASiiigAooooAKKKKACiiigAooooAKKKcilmCjqTigC5pFi17dKoB2A/Ma7uONLaBYohhcVT0O0FlYZIHmHk1bLZyT25oAecKox1NRr1575pCxJz2p8YG5QeQaAGL8vB6VJyVH1oCEDipEXBOaAGhdyCp44+AD0qNCNoGamtzlSKAFVevrSZO0j3qcLlcimFcnB9aAJMAj8KqSoTKfyq6YyqHFMigllkBVDtHfFAH0B8FfhY2n32ieL21mGZTEZVtooSQQ8bLguSMEbufl6jFct8bvAcnh+9utdbU4J49TvpHW38so67yznuQQOmeOo4r0H9m3W3uvC93o9w372wl3xg/wDPN8nA+jBvzFcP+0Vqkmq+LorCF91vpsWwgHjzHwzH8to/CgDx2Vc9KToPrViRGRyGGKvWGkNeRllYDHvQBlEdRSMCFP14q9dWUkBKsM81WmRgACCMnNAFViQ3zU/AIU051JbJpgyMHsDQAmzk00LtbPpU5+6SOpNNK/vMe2KAISxOKf5gXOe1Mc7cVCWJBoAtzRrLG28AjFcf4i0UxEzQDg8kCusV/k68VI6rKm1gCMUAeUkYOD1pK3/EWkNbymWJTsPJrAoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACtPw/bfadRQEcLyazK7LwnZeTbNO4wzdM0Aa8uAMUz6dfSlm5figfeU4oAag+WpohkZ9OaFT5QTUkOORQA8DAz2qKV8tnPFT/dhHfiqrHeDx0NAD4kyPepk+Qmooidw9DxV2KB5yFjUsTwABQAkT4jAPWrMFs91KqQqSx6V2PhL4Y6zrux/JaKHP3n4ruk+HTaDdxxthpD0agDz+Lw+1lEk9+Bs2521X1HWLFLcRWkQVgfSvTfEXht7i12tMN4GMZry/W/DcllMuSD1PFAGp8MPGC+FfFkV9cBjZPE8U6r1KkZH/jwWueutRm1TUru9upN011K0r/7zHJ/nVK4tJlDFVOBT4bNiyYyGxmgCxd2c7p5qDcMdqpQzXFupALrzXVeGmlWRlmAaMdRiu2stO0W+xDJCu5h1AxigDx9r6VvvHJz3okm8xlyBmvR9W8BQT3fl6bIA56A1yeq+E9U0uVxNAzKM4ZRmgDnZ0JlOBx7VEwKxkEc5xV7ypVyChDdTxVZ928eYMc0ARsPugUAZJYjvihyCRgUqDII7bs0AMnjBYgcAVQkUru7iul0LRb3xBqcdjp0XmTSdSeFRe7MewFWfH3h2Dw3qgsLe+jvZFiUylVwY37qf5/jXM8XRVdYbm99q9vLu+3z3K5Hy83Q49WIQZ6Yq1bODk+1QyxkLTYwVXANdJJauI1uImV1yCK4HXtLeymLqP3ZrvRKAxFMvbWO6tiHAIoA8uoq/rFk1ldshGFPSqFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFSQRNNKsaDJJxQBb0aya9vUQD5QcmvQWRYIljXgAVn6JYJp9vux+8I5qzNIXkX3FACTffyKntUBZCeh4pkUfmuM+lX0iVQoHUdaAK8sX7vg8g06KPJGepqSQdRjIzRvCEY6igCvMcKR6VXRJZWCxoSTxgVsaRpF5rt+tvYRM7uQOBX0j8NvhBZaPDFd6womusBth5AoA8e8FfDHV9fMTeS0UJ6s/Fe8eD/hVpGghZrtRPMOfm6A16CvkWluRCiJGv8KDAFYepa0HhkeFSUQEGgC1qms2Gh2pYqqRqM4UYFeU+LPF39p3cU1ixYBscdq3/EMZ1PSifvRyLjPpXGaPoiWFxJHICUI6ntQBbv7qcWJZ9xcjOa5u5spdQQT4JX7td+scE+nPAqbmUY3VU0SIQWlxZTw8M3ytjpQB5/YaYsqXELLk571oS+GnjCZjA+XI96u6vpOpWt1GlmhO+QZIHbNdlq9rLHaWhUhriOMb0P0oA8s0qEw3cwxhlB4I61oPfWttDLIWEU4XjnHNXLuRJVZ0i2TAEE4rkPEGmPeqihzvPJxQBLpHxAP9qR29zE2/OBIor1TRdbiuwVulSeHH8QFeYWPhtv7LHl2wEwwBIw5q1eammh2a2Ue6W8K5bb2oA9NufB+gaxLutnSFz/DmuQ8VfCi8Dt/Z6iRVGcr3rG8Pa1eSnzpGMY7Z4rrG+Kl1pUsMAQStkKQOSfagDw3VbGfTr2SC4jZHQ4IIxVzwroOoeItTSy02Lc55kc8LGufvMfT+favf/iB4KtvFqQ3MSJZXxxvPUe/TvXC+LNatfAmlt4c8KqyXLjN3fN98kjoD6+/QdueR89UzyGKSo5Y1OpL7orvL9F1N1RcdamiG+Idd03wDpL6B4WdZdXf5by+xyp7gH154HRfrmvKp3eV3eR2d3OWZjkknqTTJGLMpbknqaDtL9+K9HL8vhgovXmnLWUnu3/l2WyM5zc35ENwpEYqui5YZq665XrzVZkZWBx0NegQQsrCb2q4hG1R71VZvnPrT0bLLzjigClr+mLfRkgfOBwa4G6t3tpmjcYIr1ZMMSPQVzfiXShPE00a/OtAHD0U51KMVYYIptABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV1HhTTwT9okH0rD06yku5gFHy55Nd5axra2yxgcgdqAJZXBPpUJHIx25pWJJB4ApyKSwx096ALVmParg4IP502NAiqT+lK38eOlACOMO2elT6RpF1rOpwWlpGzs7Y4HSm2ttLe3cdvbqXkkYKAK+qfhT4AtvDenRXV1GrX8ihsnnbmgCx8LvANr4V0yN5o1a+YZZiM4rrNS1ewtQYrm4EbHgDODmq3ifXY9HsnfIMmOBXkMVlqHirWRd3EjRwI+5R0oA7+8194XMcKkoDk5HUUzXsT6fDPpTDe3+sj9aZp0lpLFPDOvzL8oY1X060b+0/LjdlKnOOxFAEqWUy2EQUcfxJUF7YE3cSLCdjjriug02O4mvnyhCbiOa6VbeMKuUUlenFAHGW2jGGMhY8Bu5q/beGv3gd2Ur1rp5IleMoRx7Uy2h8hCpckds0AUF0mLbGGRSVOc4rO1rw2by9W4t32nGCK6aq17K1vA0iDcfSgDyXxL4V1CC4xDCHRuSVFc/YaJKmosLi3O1B3Fe+20nnwB3TaT2NMewtncu0KFj3xQB45NYyuC7kRRLwF6ZrzjX5LO01x5gNz42nPNe1/E/S2t9NN3bMVVTyAK+adYneW5lZskk0AaF5rGUaKP5VByMVu/CbRW13xct7cAtaWAEzZ6GTPyD88n/AIDXAM/z+2Oa6/RvGF7oHh/+z9HSO2klYyTXJG93J4GM8KAMDv68V5ub0sTWwsqOF+KWl27JJ7v7u2tzSk4qV5bI+hNS1Sx0xFa+uood33VY/M30HU/hXDfEjwafEOktrGnxneo5GMEj1ryvSdSMuprc6jNJPIWBZ5GLMfxNfTvgTUrfUNJWIYKFRgHoRXmZBw5DKLz9o5SkrPovu/U0rV3V0sfHNzC9vPscYKnBBqL+LpzmvdfjB8Nnjnl1LSo8xt8xRR0rw+SJ4J2WRWVuhBr6U5xpwT6Uwrnmnt2HBpFHDHpgUAUJ/vYxSRn5x7Crcy5XnB471DbxF5diKdxHApN21ZUYym1GKu2S2xLD5QS7cACnyJugKHqeoNWXePTI1VQHuWGM9lqoJS77mOTnms6dR1G2lod2NwUMHGMJSvU6pbR7K/fucf4o0vym82JeO+K5ivVL23S4hKkVwOuac1pMWA+UmtTzzIooooAKKKKACiiigAooooAKKKKACiiigAqxZ2z3MwRB9aiijaWQIoyTXaaFpwtodzj5+tAFvS7GOygAI59ank5bIPFK0hOQOnvUXVD3waAFxng1Ytxn3xVccYPvV+zX5iSOKALY4UA9KVc/MAMk8Y9aDyoIrvPhP4Rk8Sa3F5if6Kh3OT6UAd98CvAYVf7Y1OL3iDCvdZXEae1R2VtFZWkcEKhY41wAKp6lckK6rnGPSgDgfFim6vQJD+73YxW5Y2sdvZxiBONvNNubAXEyu46DNa1qqlQFIxQBhPp+D5qrgk8ium0bTo4z9oYZdhgZ7U63twx24BrUiQIgUdqABUVfuqB9KZc3ENtGXnkWNR3Y4rm/G/jKx8MWbPO4acj5UBr5z8ZfEfVddlYecY4WzhV4oA928UfEzSdIGyCQTS+1ec3/AMZ7uS4DRRARKeg714o08txMDIxY+5p6nDYI4+tAHug+N8m4f6MuMVj618aNQutq20aoueeK8gP49OKYoOTmgD6Q8CfFu3vGW11bCSHo1euWtzFdwCW3dXQjIIr4afcku9CVYDgivRfh/wDE690Rhb3btJb8DntQB9N6pYRalYSWtyAyOMH6186/Ev4dz6Nvu7ZS8DNnjnHNe5+GfFFnrdqssEqnOMjPIrX1Kzg1Oykt5gro4x64oA+IXhAd1Yc5pQC8oXqMV6P8RfAVzoV3NOpDQO2VwKyfCXhe4vrlPl3J1P0oA56O3CSZPIwK9z+F+pwpZQxLncuBWVdeAUjcMIj8wrU0Lw3PYyK8Iwq9hQB7CBHdW+HUMjDkHmvEPi38OogXv9OjwDywA6GvUPDd8xLRysSBwAa3ry3ju7WSGUBkcYoA+GL+0e2nMbDGKgHCsCK9G+MOgNo+uYCYjbkEVwNvF5s+OcDk1MpKKcma0KE8RVjSp7ydkI9i8kKsuNx6g0SMunwlIfnnbqx7Vpu6xjLsFHvWVeMkjlou/XIrgozniJWn8J9rmuEw2SUufCNKq7LV6pW1aXRvq+nQzJWLMGJO7qc0yM/Oox+IpX3bzuFPwBGW6GvRPhm23dk6OWY8g1W1Oyju02uvanRAqMsOPUVZjJcdc5FAjzLVLJ7Ocgj5SeKpV6Jr+mrdW5O3DAcV5/PE0MrIwwQaAI6KKKACiiigAooooAKKKKACiir+j2pubtRjK96ANjw5p3AmdQe9dG7bWAHTGKbBEtvCEHp0FJjdkYoAQjIDdfWkXOM560/OAVpq/dPFACj723rWnbIQik9M1QgH7wEjmteLmPp0oAs2Fo91dxwRAsXbAxX1r8L/AA3H4e8OQhows8gDOa8d+B3hM6nqwvrlP3EHPI6mvojUruOztwD1PCigCfzdykj7orGurzlgkec8dKi+3vDFt67zxV63RXaNwBkryKAKEkilV3cEjFSRIY0XC++az9RkUXIVFO4Vo6QJLlsPzEvWgDWsoiil26tzXP8AjzxfaeGNOd3cG5ZTsTNW/GPiO18M6PJdTsNwGET1NfKHjXxNdeINUnuZ5CVz8q+1AFbxZ4ju/EF/Lc3chbJ4HoK552JZR2FAOSQOnvTwnHNAEiABckDIp3B3YHamgjJ+mKM4LHtQAp/pQOgHrTR6dqXP7wDFAEu/g+uahI/eMAcDFOYj5l96YOrEHJxQB0XhDxRc6HcBkkbyt2GGa998G+LDemGRZiY3bBUnpXy5CuV+b611nhHXn0m7hy58vrigD6w8R6Va+INKaCUryMqx7Vx/g/wlcaffyFZFMC8cVxc3xLIth9nc+ld98JtcOqWM3nMd+cjJoA39QcxyqhTCjjOKpqGinLcbCe1dRcQRzIdygkDiuYvYvJYDcRg5xQBi3U1zGpltBzu5rf0PUbuS1UMwMmeQ3Ws2N0+xueBk5qve6lAkSfZ32zDgEUAc58cfsl/poLREXMZxnrXz5vaHzABhvWvoqK2bWNXjs9RUyRyN94ivPPir4Bl0G8M1mM2z8jiplFSVpG1CvUw8/aUnZ9zyyRndgXJJ96UphTnmnt/rdrDBFKcEkelNK2iM5SlNuUndsqPGOcU0jEbcdasgYB75NQTA8ADjNMkrNlTgHGe1SB/mHGD6io5QdwpgJDHnBPY0AXd+4EHkVy/iTSVdGmiXDDmt1GKue1WHUTIVcZGKAPKWBViCMEUlbfiLTjbXDSIPkNYlABRRRQBp+JdJfQvEOpaTLKsz2Vw9u0ijAYqxGQPwrMrqfip/yUrxR/2Erj/0Ya5agAooooAK67wzamOESkYzXMWUXnXMaepr0K0jEVrtAwAKAHOeSAOKZ36/hSHORzRztOODQBIcHbx1FNYBSe+aaCcD1pT8w+lAFuzj3EZGcV0OiabNqOoQ20KktIwHArG07HmBcZJFfQXwJ8JZlOrXkeFX/VgjvQB6r4H0OLw/4ft7ZVAfaGc+9ZfiHUY31ADO7bwo962/E2omytCEOGYV53pryXd8ZpQWVTnNAHU2EvnYdkGF9avy3mz59+0KKzo18m3+Tuc1nX0pZCgJz6UAW7q6bUrryrQfOTya6exRNF0h5LtwAgLOTVLwrpCWsAupQBI4zz2ryr42+O8ltK0+XCjiQg9aAOC+LPjOXxFq0ixuRaRsQi57V59KQUznnNJKTLk5pxjHl+9AAoyCRUg4LdxSDgD1FBPOM9TQAn8Rxikb7tA6fWhcY57UABHOKTPzc9qQZ3DuDT3ABoAG+8frQoG2Qt6cUuDjrzQ33MHvQA1B+7A77c113g7wB4i8UvG+nWTpa4wbq4ykQ+h/i/4CDXqnwG8KeEtW0UalLbC91e3by54rkh0iPO0qmMYI7nPIOOleh/FPxIvhPwVd3ULCO6kH2a1C8YkYHBH+6AT+FAHytr9pHo2s3OnQXS3aW0nlmdV2hmHDYGTwDkA98Zr0nwHr7WGnxiEYbGCa8dnkJYkk5Peuj8Iaq1tcCOc5jP6UAfWHhLWYtX08EODKnDDvTtZtcfP/AA4rxDQPEU2gapHdxNm2b769iK9y0PWLLxHp4lt2DKcErnpQByrgTebBgqRwKw5dMK3kQB3KDk5r0C+05beQyxrkGuV1WJ1uFkh7/eFAG7osEIuoWCgMPWrvjfR01nQZ4CuZAMqazLJWCwyLnIUE11drKJoQSOccigD488ReGrmz1CYFchTXNSqYmfPavpb4p6CsbPdxR8OOSPWvAtb0uRFkmxxuoAwzggZ+tMcld3fNPc4ABHHrTGPyMTzk9aAIJsbBtHPpVeMByox1POauOvOByMUwRgduQKAKzjDPt+YZ6HrRA5Ukg/ganKqOTycdaruMAnrigCLV7RLyzYbfnxXnlzC0EzI4wRXptscjB5Fcv4s04f8AHxGOe9AHKUUUUAX9d1OfWtavtTuwguLyZ55Agwu5jk4HpzVCiigAoopQCSAOpoA1vDkJkvAwGcGu2k4THeszw1YC1thIw+ZhmtOQ7mOaAIW5AwePWk79OvelK4Ge1KRjb3B70AIMFsdfQ1Ko45GahzhjjpjIq3a4lcL3PagDsPh14el1zVraFF+Uv83HavsTRdOh0rTIbSAAJGuPqa8t+AfhoWWlf2jMgEj8LkV6tfziGB+fmxQByfihxd3nlgfLjaai0i3hg2xoAQR3701g0mobz92hGMc/mKMY6UAWJpVVCMYJPAp+jaX9rvBLKMotSi1N/dKUXAA5q74k1iz8LaHJczMqlV+Uf3jQBz/xV8YReGdGaC3YfapBtCg/dFfKeq3j3t08zsWdmyc1p+MvElz4h1ia6uJGYM3ygnoKwwMuCaAEUfe4xzUvVee4pvQN3pc8AnoBQAZyfoKAwbZxyQaRfQd6RARJjuozQAh6YPbpTgOCOpxSP0U4604jAPPIoAaoBA7Cl5303scH8KfkEA9xQAHGRWt4b0G+8SavbaZpce+4mbqeAijqxPoBWS4644NWrK+utOuYbqwuJba6jbcksbFWU/UUAe1+I/Fln8L7GDwz4PME+pRusmoXcibgz91Iz1OMEfwjjryOA+J3j+58czaeXt/skFpGQYVfcDIT8z9B2AAHbn1rjJJHmeSSZ2eV3JZ2OSx7kn1qPvz1NADG5bGakhkKbipwelRsudp9akX068UAdvos41DSzA7fMBjNbfgjxNc+DdYXzXaSwfhhXAaBeta3ZUt8pHNdXqMUU+nZyD3oA+ptJ1G11ewS4tZFkicdj0rF1ax8i4aZFyteBfDTx5P4c1EW8rl7N22lSegr6Vs7q11vTVmgcPFIM8HpQBkW8q+UcAA45Fa2kSrIpwegrFvrKazd3HMbHtVvQ5MTEDp6UAaOuWCahp0sMihsjjNfNnjuBLBZ4MbSTjBr6irw/wCOGhIrpcIOG5oA+fics2D04wajZSEG08dwallQpKyngAmmdVUEZBoAb0KqBjuQaYzE9O5xUrfM+c5AGKaAC/pgUAVJASWOcehqBt2CG4JPUVbkBMefU1XkAOAvB9KAEVtmfU96W+gW6snRgCccVCSQy+9Wbd93y0AeZ3kXkXMkZ7Goa3vFtr5N9vUYDVg0AFFFFABWpoFn9pvFLDKKazFGSAO9d14dtBa2QYr8xGc0AaxAijVQcYqM+o5FRSvnB7UK2RgUASFcE4OVIpAMjjp3pYSD15NTKgIxj8KAKzLgjbzjvWx4K0+TUtdtoYwSN4B/Os14yVyPyr2r9nTw2t1qTX8yfJH/ADoA+idAsY9L0a2toxhY0GfrjmsDVNUWW6chhsXj8K0vGWrf2Vo8rrzIwwBXlekzzTyvLIxwx6UAdrbXEc6nackGtSC0FwVAH8QFcxYwuP8AVqeTmu70SIxWpkmG09eaALE0ltpVjJNKVSONcsT3r5X+LfjyXxLq7QQMRZxEqq54rsfjp8Q1kDaTpcuUHEjKeteC9f3nUmgCVvmlAHTrUgB2Hnmo4xk5PcVKCQVFACjDKSKQ8J149KIh98ZpeqZ96ADGOQaVeZAc87aRT8rA8ilHyvkelADeDmnHBTHcjim9OfWpMcpnt1oAi/jB6cUp5BXuaFGV565pyAE4NACSZ+bPpTnOUX2prcjB70rD5WOemKAFHOQeuaQffB9AaUD5hjvzTT1yPXFACDGxR3zmnJ94n1Wmt8uMURk7Rnp3oAchwDjrWlHqcv2NockgcYrKPGMdzUkTFdzHoKAJVV9xKox7mvTPhb8RJdCuEs7x2a1Y4wT0rCtktX0l2jCl2WuTubSaIlyMAcigD7bsLy11exSeBlkieofsCwXfmx/KGPNfN3wr+IlxoN3HaXrs9o55BPSvpXSNWs9XtEntJVdWGcZ6UAaAORxXF/FHT0vdBJI+ZT1rswAB7Vh+MyP7DmU45FAHyH4kt1trxlAwRWMp+YdsCui8WxSm9mdh8pY4rmmIwQPTigBEbOSRg5oPALfhSoegznApuMjB5Gc0ANZcjA6Cq0qkZJ6Y4q4xPXoahmXI5HSgChnJAPQCnwsUYbeR6U2dQrcGmbuVz270AVPFlv59h5ijlea4SvTbpBcafIp7jrXm06eXM6ehxQBHRRRQBf0W2NzfRrjIBya79gIogo7VzXg63+/MenSujujkEZxigCu3Ix70KcfWjGc44puDjrjBoAljbPHSrtswY9eelZjZBBHWrFrJtPPU0AbEFvvYADJB6V9U/A7Sf7P8MeYRhpDXzR4eKy3cSk5JIr688AosXh2BV44yaAM7x3AJmVZD8vHFc1aWcUkuyAflXZazbf2i7sAcq2Kl0bRYbMmaTAxySaAGaFppt4DNd4RV5yfSvOfiz8U4LK1uNN0Zw8pBVpFPSqHxo+KK22/SNGkySNsjqf0r59klmmPmyEsWPJNABcTSXcrTTMWdjkk0RjII9BmqyyHgenFWY8kN6laAJ0x5YHenEHJHpzUUXIA71L0Zs+lAAOXOOxpWHygDpmkT5W+opWwMDsaABTxzTicZB/Cmc449adJz+NADR93B9acSdxHfFJyWHpRkFz6k4oAQ/KPpTgD5mAeSuaRzyPfg0chgR1HFAAegz6UckD3FICME+lKTgUAAY7UJHejvkDjNKDnYB2oj5KjPPJoAaRk496byqEnp0pc9SfvE08DCnPODQA3qPpxQ6koF/Ogjr7mpA2529aAL+kXZt5lR2Ow8YrY1uaN40QDtnIrlIyclielTG7cjDtkUAXlswWLIRjtXYeDfFF7oU6hJmMeQCua4m1un8sBeVJqOSd1OVbkGgD6ksPHsF3arlxuxzzVPxH4mSbS2AfdlTivnbT9UuUYbGYZroZtYllgSLcenNAFfxJKJomJIPU1xDHnPtXTaxIPs3X5u9c0xyDx7CgAXk4PWhckkjtScbyOwFNDbQG/WgB5wQPftQ/CHuDSZDEeopMnaQeeaAKEgO8/WmkYJzwanmUByBVdjgHPJPSgCxb5ZGUdMdPWvPdYTZqMwxj5q9Btc5UN09a5LxLaM2quVGQQDQBz1FFOQFnUDqTigDuvDaCLTlwOTzVtzyc8g03TYfKsEDcMBTyARjv3oAZ6UoHzEGgnA2j86Bgjjg+tACCMt25qR4Sq5qxaAM2SOPSrgRSOe9AFnwezm+jB6g19a+Db4DR4oy2PlFfKOhslteAg163pHisW1miB8YHXNAHu1vLawQPLLIqqOSTXjHxc+Kwgil0/SXxn5S6nrXLeNfiJK1o0MEhVSMcHrXjF5cyXVy0srEsT3oAstNJd3bTTsWdznJq9tAUj05rMhOGGfrWkW+TJ7igCk6gzErVlFI7cgZqCL5pDkVakOAM8fLigAjAye2RmnevrimrkLj8M0pOCBQAoGQpz0HSnMcqvtTF7D24NLngHuOKAFToOc96U8ge9IOP5igfdBz0oAEOSD6UY+VyTznNAPzbehozwW9OKAFYZC80A5UgimscDk9DQpOAp7mgBR6etKRlCPU0IOMg+1IDjb7HmgAB4Uj1xQ3BJHrxQANoHuaXPU9QBzQAj4yR3FOBB3e9NHIOT70AZJxxkcUAL/AAn601DjLf7VNJPlMfeo93ynPSgB5OAw9TUbHgg05+cGo8Ann+9QBYs5TGNo6VPFFv8AmJ71WyBK3tT/ADiirgZ3GgDahCRoTjBFSQybpCc/KKyzckw4I5zRHNsjz3oAfqtwzNtDZ5rOPJHt1qST5mZvU9KY+QfY8UANP3j6GjbmMAetNdtuSOR0pkbklc9qAHgEYx9KVSCQfTrSxkMff0po6tnoeKAI7hMkGqrr83XHerkuTGM+mKqHO3kZBoAdASHA7+tUNXtg94WPoOlXoDhwOtPuoy0mQRjFAHmNaXh+3FzqUat90HJrNrpPBkYN27kdsZoA6ufAwo7cVXYdeelSXBO4g9P51CCOD/D6UAKex7Gkb2PNJk9O38qXscfe7GgC9bcITjpT2lIBOeKZGcRgjv1qPhsjtQBJFcP5gxxWqt86WxJY+w9axlIGD29ak3GTPHHYelAFa8uJLiVmkP0HpVY/d5q7PbkKSKplcAjuKAJo35HrirnnApt9qoMMMpHfpU0HJIPc0AWrdcAHrUrHc+08jFJGCBigjnI69qAJEP7pc9KRh8woXG3HahT8xB6YxQApwAtK2QG9+aY4J2jOeMU7qvqVPSgBRyCfagj5R6MaU4GSKRs7V+vFACnluOtIvO6l6MR3FM7MvQ44oAM8Nn1pFP7wewpG7dveo9xLkfhQBYHyhcjnqaOgbjrzQeSDSjqpHIPWgBQRke4zTf4SP7xpBwxB6jpQPuk+lAASNje5wKVT+9+gwKaDyPYUKckk8YFACH7pqJuAxPSpTwrZFMlXMJHckUAOIwBj0qM4BGKlznr6VEy8jAoAcTudvengjci+1V13AZz1pwchxnqOBQBZzyD2pXbCnHXFRK+CBSuwGD68UAO6gUx8jn0GSKUHB57VFI5kG1TjceDQA1O3ORTimGyO9CKS7HuOCPWplUDHof0oAi2/Nkf/AKqeBkN9MilUYJB7Dg+tI3yrgdTQBGMMufUZqvIQOOmKnjOWOB8oPT2qrcqO3figBEBDCrTruIJGeKqoSCAfzq4BuAO7HtQB5TXXeC0/dTN6GuRrs/BgxayGgDWnOX3Y6cUzb/PFOnb5qjzk89KAA/ex2p0XL5xkjpXeaJ8Mr7WfD+mahBqmnxz6jFczWtpL5geRYGIk+YKVHbGSOo98cTbJlzQBZbAQYqqX+cjpVmf7hIqiWzIOeKAJx86e3artsmPmqrAOcdhWigC9OhFAEFwOD7VmMcs3Fad2doPfNZxUmXHSgBg5VfapbZcy49eaeyKkXXmktDmYY60AXo+NxHbtQow27sR0pfcd+tDcL79qABOAvpigDJPqKE+9nt3FCnO5T+FAC/xANwc0qcyY70h64PWlHDc9aADIw35U0j5QR2NKTjbnuaCcO4IoAGO4hvWkY/P9abjaRz3pH4OR1BoATJKLTTw7Y9M04dAB600j5j9aAJUODz2WlzgDHWm8bz2OaBzux/DQBI5BYnHTikj+4Qeg5oB4+vNLF3B7DNADeu5vQ0qgMqfUk0gyEwOpOTSnAUEdhzQA0k7MGkk4C+4zTnxgkdCKa5xHntjFACE55HpSdiR6YpTgNn2pv8PJoAZMwXIx71FGcyr6VJIDhiewoRcHI6nFACByX54AzQh3uFPTFOcAM3pmkReWPc9KAJH7Ckij+4G4PWnxru5PGKe/JHHegAUYQeuetKeCT7cj1pm/kg8YprSA7cdPX0oAePuAjof0pkrYUVu6Hoa6n4Q8T601w0baP9mAhCZEvnSFOueMYzXMgkyr/doAehwx5qGT5pMHrU+Bu9ielQXA+dsfd6/SgCNfvH+VaMS/IMis8YYj0z1rQjyyg0AeTV2Xg7JtXJHA4rja9A8NweRoykjl6AJ35kb0pmcDPpStwxA5p3BP4UAel+HvipJpPhPS/D02l/adJht7u3vIvtOz7UJn3AghfkKZIzznJ6V57bhSzMgZUycBjkgdsmqhO4YHar1sAIcdKAEuD+7wOoqoo71YnOQPrTFwFOKAJrT71XsjAx2rPtyNxA69aunjknjFAFS6b5wR070pjDsjL3qOQkk471LACIcnrmgCtO2eMcg1JY8ybu/aoJDmZ6mss8nHuKALwPJbsaTBwRT+PKOO9M/jAPAIoAVSOW/A0ADaD2zQRgNSjnav40ABbJAP50EjDZ7EUin5uaD9056k0AGQZSDQ/DKT34NMPyzZPfinAZ3g0AIfvle2eKMktg9CaB1GRSNny/daADGC2e1IxyCB3FKTk/zpAcSD6GgB2M89u1Cn5wPWkhPymnEZyR0UUAAOVbHrnFOH3SQepxTE6g5606PIG0jvmgAZuCO4pGP7ts9SwpTyeBySaCP3b5+tACgDbhqa/AI7EU7qijvTH4Vucg8CgAcdqiIGB9alOflI9KaQBgZ60ANZcxsf7xoTqPY1IuPK49aQ4Xn1oAiJ+Rv96kjYKciopCeVHTNCHDEd8ZoAvKQf50nUrn1qsswIXtVmLB2nvQBXmb5iMUQja2QM8dKndQWPHSlRQDjHbJNAG74X8V3HhvTdVsE07Tb+z1LyvtEV9G7KfLJZcbWXuc/gKw7iRbm8nuEgigEkjP5MQISME52qCScDoMk1HJgr6ljzUakknaee1ADcDdnPFQ3DEMCPWpmOG98VFdAfL6d6AIl6nHFadqcQisvJ4rRt2xEMigDygdRXpVhxo8OP7tFFAEI6Ch+OlFFABH2q8nEYA79aKKAI5fvGo+4HvRRQBbtVAbOOadMTtoooAqjoPrU5OIePSiigCiPv1ZtfvEUUUAXv4aYeWFFFACtTk+8fpRRQBGv3Se9PHUUUUAMkHNEZzmiigAY/KlNbp+FFFAA3DUjf6wDtiiigAj4RjT1PH1FFFADsDBpEOX/GiigBehJHXNI33aKKAHDr+FIw/cD60UUAJ/Gv0plx0oooAIf9TGfal6oPrRRQBWP3z+NRr/rW/wB2iigBp4fAqxbsd5GaKKALT87s1DKx2E55oooAgYnNTQf6s0UUARycFD60l10HuKKKAKq960rQZhGaKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a section from a CT scan of a 72-year-old woman with multiple myeloma treated with monthly bisphosphonate injections. She complained of left-sided jaw pain and swelling following dental extraction. This coronal view of the mandible shows several areas of disruption of cortical bone (white arrows), a pathologic fracture line (red arrow), and a large area of central bone loss (yellow arrow) suggestive of tumor and/or abscess formation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Reed Drews.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_45_8927=[""].join("\n");
var outline_f8_45_8927=null;
